肥満と脂肪エネルギー代謝 ―メタボリックシンドロームへの戦略―

出版社： 建帛社
著者：
発行日： 2008-04-25
分野： 臨床医学：一般  >  栄養/食事/輸血
ISBN： 9784767961248
電子書籍版： 2008-04-25 （初版）
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

2,145 円(税込)

購入する

商品紹介

現在大きな社会問題となってきている代謝性疾患，メタボリックシンドローム発症に深く関わる肥満について，基礎・臨床的研究の成果をわかりやすく解説し，肥満と身体の関係を新しい視点と手法から捉える。
ヒトを対象としたアプローチ（消化管ホルモン　ヒューマン・カロリメータ　運動の役割　褐色脂肪）　エネルギー・脂質代謝調節の分子機構　肥満病態と食品・医薬品による予防・治療　ほか

目次

  • 表紙
  • 序文
  • 目次
  • 序章 肥満研究の潮流
  • 1. はじめに
  • 2. 世界の肥満研究の推移
  • 3. 肥満研究における主要な成果と手法の開発
  • 4. 臨床診断基準としのて肥満症, メタボリックシンドローム設定の意義と戦略
  • (1) 肥満と肥満症の区別
  • (2) メタボリックシンドロームとは
  • (3) メタボリックシンドロームの疾患概念を確立する意義
  • 5. 肥満の社会的背景と医療経済
  • 6. おわりに
  • 第I編 ヒトを対象とした研究アプローチ
  • 第1章 消化管ホルモンによる食欲・体重調節; 肥満治療の切り札か?
  • 1. はじめに
  • 2. レプチンの発見と食欲・体重調節ループ
  • 3. 消化管ホルモンによる食欲・体重調節
  • 4. 一塩基多型からみた食欲調節ペプチドの意義
  • 5. 食欲調節ペプチドからの創薬
  • 6. 肥満外科手術
  • 7. おわりに
  • 第2章 ヒューマン・カロリメータによるエネルギー代謝測定
  • 1. エネルギー消費測定の意義と測定方法
  • 2. ヒューマン・カロリメータの仕様
  • 3. 睡眠時エネルギー代謝
  • 4. 肥満者のエネルギー代謝
  • 5. 生活習慣の改善などによる安静時エネルギー消費量増大の可能性
  • 6. おわりに
  • 第3章 肥満・メタボリックシンドローム予防・改善における運動の役割
  • 1. 肥満・糖尿病と自律神経
  • (1) 自律神経活動の評価法
  • (2) 心拍変動スペクトル解析の応用
  • 2. 運動による自律神経活動の賦活とその生理学的意義
  • 3. 肥満・メタボリック症候群における運動の効果
  • 4. 運動と筋細胞由来の生理活性物質
  • 5. 骨格筋電気刺激による他動的運動の効果
  • 第4章 褐色脂肪と肥満・メタボリックシンドローム: 実験動物からヒトへ
  • 1. はじめに
  • 2. 褐色脂肪とUCP1の活性調節
  • (1) UCP1の活性調節
  • (2) UCP1の発現調節
  • 3. 褐色脂肪の機能と生理的役割 ―動物実験からの知見―
  • (1) 体温調節
  • (2) エネルギー代謝と体脂肪調節
  • (3) 糖代謝
  • 4. ヒトの褐色脂肪
  • (1) 褐色脂肪はヒトにはないのか?
  • (2) PET-CTによるヒト褐色脂肪の検出
  • (3) ヒト褐色脂肪の存在部位と頻度
  • (4) ヒト褐色脂肪の機能
  • 5. おわりに
  • 第II編 エネルギー・脂質代謝調節の分子機構
  • 第5章 抗肥満に関わる骨格筋の役割: カロリー制限と運動療法の理論と実際
  • 1. はじめに
  • 2. カロリー制限および絶食時の筋肉代謝
  • (1) 絶食時の体内でのエネルギーの動き
  • (2) 筋肉でのエネルギー消費量の変化
  • (3) 絶食やカロリー制限に伴う筋肉での遺伝子発現の変化
  • 3. 運動による筋肉代謝
  • (1) 運動強度, 運動時間による脂肪燃焼の程度
  • (2) 運動中の脂肪燃焼亢進機序
  • (3) 運動トレーニングによる脂肪燃焼亢進機序
  • 4. ヒトではカロリー制限と運動は同程度体脂肪を減少させる
  • 5. 体脂肪を減少させるための, カロリー制限, 運動量の決め方
  • 6. おわりに
  • 第6章 AMPキナーゼによる生体エネルギー代謝調節機構
  • 1. はじめに
  • 2. AMPKの構造と活性化機構
  • (1) AMPKの生化学的特性
  • (2) AMPKの活性化機構
  • 3. AMPKによる代謝調節作用
  • (1) 骨格筋におけるAMPKの代謝調節作用
  • (2) 肝臓におけるAMPKの代謝調節作用
  • 4. レプチンによる代謝・摂食調節作用とAMPK
  • (1) 骨格筋におけるレプチンの代謝調節作用とAMPK
  • (2) レプチンによるAMPKの細胞内局在制御と脂肪酸酸化
  • (3) 視床下部におけるレプチンの摂食抑制作用とAMPK
  • 5. おわりに
  • 第7章 脂質代謝関連遺伝子の転写制御と肥満
  • 1. はじめに
  • 2. 肝臓における遺伝子発現調節によるVLDL分泌制御
  • 3. 遺伝子発現調節による胆汁酸合成・HDL産生調節
  • 4. おわりに
  • 第8章 胆汁酸によるエネルギー代謝調節機構の分子メカニズムと臨床応用
  • 1. メタボリックシンドローム
  • (1) 世界に蔓延するメタボリックシンドローム
  • (2) メタボリックシンドロームの診断基準
  • (3) メタボリックシンドロームと高コレステロール血症の併発
  • (4) メタボリックシンドロームにおける脂質代謝異常と非アルコール性脂肪性肝疾患
  • 2. 胆汁酸
  • (1) 胆汁酸の生合成と遺伝子疾患
  • (2) 胆汁酸の生合成制御
  • (3) 胆汁酸の腸肝循環
  • 3. シグナル伝達分子としての胆汁酸
  • (1) 胆汁酸による分子制御
  • (2) 胆汁酸による脂質代謝調節
  • (3) 胆汁酸によるエネルギー代謝調節
  • 4. 胆汁酸代謝調節を介した肥満・糖尿病治療への新規アプローチ
  • (1) 胆汁酸吸着レジンの血清コレステロール低下作用
  • (2) 胆汁酸吸着レジンの胆汁酸代謝・糖代謝への影響
  • (3) 臨床検討における胆汁酸吸着レジンの糖尿病への影響
  • (4) 胆汁酸吸着レジンのメタボリックシンドローム治療薬への可能性
  • 5. 胆汁酸代謝と糖・エネルギー代謝
  • (1) FXRと糖新生の制御
  • (2) 胆汁酸とインスリン感受性・エネルギー代謝の制御
  • (3) FGF15/19による生体機能制御
  • 6. おわりに
  • 第III編 肥満病態と食品・医薬品による予防・治療
  • 第9章 アディポサイトカインと病態
  • 1. はじめに
  • 2. レプチン
  • (1) 摂食抑制作用機構
  • (2) レプチンおよびレプチン受容体遺伝子異常と疾患
  • 3. アディポネクチン
  • (1) 発現調節機構
  • (2) アディポネクチン受容体とシグナル伝達
  • (3) 疾病治療薬としての有用性
  • 4. PAI-1
  • 5. ビスファチン
  • 6. TNF-α
  • 7. レジスチン
  • 8. MCP-1
  • 9. おわりに
  • 第10章 脂肪組織リモデリングの分子機構と医学応用
  • 1. はじめに
  • 2. 脂肪組織におけるマクロファージ浸潤の分子機構
  • 3. 肥大化脂肪細胞におけるケモカイン産生増加の分子機構
  • 4. 肥大化脂肪細胞におけるMAPKの変化
  • 5. 肥大化脂肪細胞におけるMKP-1遺伝子導入の効果
  • 6. 脂肪細胞とマクロファージの相互作用
  • 7. 炎症性アディポサイトカインとしての飽和脂肪酸
  • 8. n-3多価不飽和脂肪酸の抗炎症作用
  • 9. おわりに
  • 第11章 肥満・メタボリックシンドロームと食品機能
  • 1. メタボリックシンドローム
  • (1) 背景
  • (2) メタボリックシンドロームの定義と診断基準
  • (3) メタボリックシンドロームの疾患概念を確立する意義
  • 2. メタボリックシンドロームに対する有効食品
  • (1) 食品の有する機能
  • (2) 肥満症に対する有効食品
  • (3) 核内受容体リガンド機能を有する食品成分の探索とその有用性
  • (4) 肥満と炎症: 食品成分による炎症性因子の分泌抑制作用
  • (5) 食品成分による抗炎症性因子の分泌促進作用
  • 3. おわりに
  • 第12章 脂肪細胞制御による肥満・糖尿病治療の可能性とその展望
  • 1. 背景: 脂肪細胞制御の必要性
  • 2. 肥満における脂肪細胞数の意義
  • 3. 脂肪細胞のライフサイクル (生活史)
  • 4. 脂肪細胞の増殖制御機構
  • 5. 脂肪細胞の肥大と増殖のクロストーク
  • 6. 脂肪細胞数とインスリン抵抗性
  • 7. おわりに
  • 終章 肥満研究の今後の展望とメタボリックシンドローム対策
  • 1. はじめに
  • 2. 肥満, メタボリックシンドロームとアディポサイトカイン
  • 3. 食事と運動から見た肥満
  • 4. おわりに
  • 索引
  • 責任編集者 / 著者
  • 奥付

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

序章 肥満研究の潮流

P.9 掲載の参考文献
1) Shell E. R. (栗木さつき 訳): The Hungry Gene: The Science of Fat and the Future of Thin (邦訳:太りゆく人類 肥満遺伝子と過食社会) 早川書房, 2003.
 
2) WHO:The world health report 2002-Reducing Risks, Promoting Healthy Life.
PubMed
3) 梁美和: メタボリックシンドロームとは. メタボリックシンドローム 実践マニュアル(松澤佑次 監修, 船橋 徹 編集), フジメディカル出版, 2005, p7-16.
 
4) King D.A.,Thomas S.M.:Big lessons for a healthy future.Nature 2007;449;791-792.
PubMed
5) 古川雅一, 西村周三: 肥満に伴う糖尿病や高血圧性疾患の医療費に関する研究. 京都大学大学院経済学研究科 Working Paper(http://repository.kulib.kyoto-u.ac.jp/dspace/handle/2433/26467/browse-date). J-57(2007).
 

第I編 ヒトを対象とした研究アプローチ

P.23 掲載の参考文献
1) Zhang Y.,Proenca R.,Maffei M. et al:Positional cloning of the mouse obese gene and its human homologue. Nature 1994;124;188-198.
 
2) Farooqi I.S., Jebb S.A., Lanqmack G. et al:Effects of recombinant leptieficiency.N Engl J Med 1999;341879-884.
 
3) Kalra S.P.,Dube M.G.,Pu S.,et al:Interacting appetite-regulating pathwaysn the hyight.Endocr rev 1999;20;68-100.
 
4) Inui A.:Transgenic approach to the study of body weight regulation. Pharmacol Rev 2000;52(1);35-61.
 
5) Morton G.J., Cummings D.E., Baskin D.G. et al:Central nervous system control of food intake and body weight. Nature 2006;443(7109);289-295.
PubMed
6) Kojima M., Hosoda H., Date Y. et al:Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999;402;656-660.
PubMed
7) Inui A.:Ghrelin:an orexigenic and somatotrophic signal from the stomach. Nat Rev Neurosci 2001;2(8);551-560.
PubMed
8) Batterham R.L., Cowley M.A., Small C.J. et al:Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002;418;650-654.
PubMed
9) Inui A.:Neuropeptide gene polymorphisms and human behavioural disorders. Nat Rev Drug Discov 2003;2;986-998.
PubMed
10) Inui A.:Cytokines and sickness behavior:implications from knockout animal models. Trends Immunol 2001;22(9);469-473.
PubMed
11) Inui A.:Eating behavior in anorexia nervosa-An excess of both orexigenic and anorexigenic signaling?Mol Psychiatry 2001;6(6);620-624.
PubMed
12) Inui A.:Cancer anorexia-cachexia syndrome:Current issues in research and management. CA Cancer J Clin 2002;52(2);72-91.
PubMed
13) Chaudhri O., Small C., Bloom S.:Gastrointestinal hormones regulating appetite. Philos Trans R Soc Lond B Biol Sci 2006;361(1471);1187-1209.
PubMed
14) Batterham R.L., Ffytche D.H., Rosenthal J.M.et al:PYY modulation of cortical and hypothalamic brain areas predicts feeding behavior in humans. Nature 2007;450(7166);106-109.
PubMed
15) Asakawa A.,Inui A.,Kaga T.et al:Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin. Gastroenterology 2001;120(2);337-345.
PubMed
16) Nakazato M., Murakami N., Date Y. et al:Kangawa K., Matsukura S.:A role for ghrelin in the central regulation of feeding. Nature 2007;409(6817);194-198.
 
17) Shintani M., Ogawa Y., Ebihara K. et al:Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes 2001;50(2);227-232.
PubMed
18) Date Y.,Shimbara T.,Koda S.et al:Peripheral ghrelin transmits orexigenic signals through the noradrenergic pathway from the hindbrain to the hypothalamus. Cell Metab 2006;4(4);323-331.
 
19) Cummings D.E., Overduin J. Gastrointestinal regulation of food intake. J Clin Invest. 2007;117(1);13-23.
PubMed
20) Zorrilla E. P., Iwasaki S., Moss J.A. et al:Vaccination against weight gain.Proc.Natl. Acad Sci USA. 2006;103;13226-13231.
PubMed
21) Zigman J.M., Nakano Y., Coppari R. et al:Mice lacking ghrelin receptors resist the development of diet-induced obesity. J Clin Invest 2005;115;3564-3572.
 
22) Neary N.M.,Smoll C.J.,Wren A.M.et al:Ghrelin increases energy intake in cancer patients with impaired appetite:acute,randomized,placebo-controled trial. J Clin Endocrinol Metab 2004;89;2832-2839.
 
23) Farooqi I. S., Keogh U.M., Yeo G.S. et al. Clinical spectrum of obesity and mutationsin the melanocortin 4 receptor gene.N Engl J Med 2003;348;1085-1095.
 
24) Pantel J., Legendre M., Cabrol S. et al:Loss of constitutive activity of the growth hormone secretagogue receptor in familial short stature.J Clin Invest 2006;116;760-768.
PubMed
25) Holst B,Schwartz T.W.:Ghrelin receptor mutations too little height and too much hunger. J Clin Invest 2006;116:637-641 2006
 
26) Mller L.J.,Holicky E L.,Ulrich C.D.et al:Abnormal processing of the human cholecystokinin receptor gene in association with gallstones and obesity. Gastroenterology 1995;109(4);1375-1380.
 
27) Dunstan C., Step hen B.:The Obesity pipeline:current strategies in the development of anti-obesity drugs. Nat Rev Drug Discov 2006;5(11):919-931.
 
28) Erondu,N.,Gantz,I.,Musser,B.et al:Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab. 2006:4(4);275-82.
 
29) Kamiji M.N., Inui A.:Neuropeptide Y receptor selective ligands in the treatment of obesity. Endocr Rev 2007 in press.
 
30) Gantz I.,Erondu N.,Malick M.et al:Efficacy and safety of intranasal peptide YY3-36for weight reduction in obese adults. J Clin Endocrinol Metab 92(5):1754-1757, 2007.
 
31) Romanova I.V., Ramos E.J., Xu Y. et al:Neurobiologic changes in the hypothalamus associated with weight loss after gastric bypass. J Am Coll Surg 2004;199:887-895.
PubMed
32) Suzuki S.,Ramos E.J.,Goncalves C.G.et al:Changes in GI hormones and their effect emptying and transfit times after Roux-en-Y gastric bypass in rat model. Surgery 2005;138;283-290.
PubMed
33) Sjostrom L., Lindroos A.K., Peltonen M. et al:Lifestyle, diabetes, and cardiovascular risk,factor 10 years after bariatric surgery.N Engl J Med 2004;351(26);2683-2693.
 
34) Guijarro A., Suzuki S., Chen C. et al:Characterization of weight loss and weight regain mechanisms after Roux-en-Y gastric bypass in rats. Am J Physiol Reghl Integr Comp Physiol 2007;293(4);1474-1489.
 
35) Balkau B., Deanfield J.E., Despres J.P. et al:International day for the evaluation of abdominal obesity (IDEA):a study of waist circumference, cardiovascular disease,and diabetes mellitus in 168,000 primary care patients in 63 coutries. Circulation 2007;116(17);1942-1951.
 
36) Marx J:Cellular warriors at the battle of the bulge. Science 2003:299;846-849.
PubMed
37) Torgerson J.S.,Hauptman J.,Boldrin M.N.et al:XENical in the preventation of diabetes in obese subjects (XENDOS)study:a randomized study of orlistat as an adjunct to lifestyle changes for the preventation of type2 diabetes in obese patients. Diabetes Care 2004;27(1):155-161.
 

第2章 ヒューマン・カロリメータによるエネルギー代謝測定

P.43 掲載の参考文献
1) Hill J.O.:Understanding and addressing the epidemic of obesity:an energyalance perspective. Endocrine Rev 2006;27;750-761.
 
2) 健康・栄養情報研究会編:厚生労働省国民健康・栄養調査報告(平成16年度) . 第一出版, 2006.
 
3) Weir J.B.:New methods for calculating metabolic rate with special referenceo protein metabolism. J.Physiol 1949;109;1-9.
PubMed
4) Westerterp K.R.,Kayser B.,Brouns F.et al:Energy expenditure climbing Mt. Everest. J. Appl. Physiol 1992;73;1815-1819.
 
5) Westerterp K.R.,Saris W.H.M.van Es.et al:Use of the doubly labeled water technique in humans during heavy sustained exercise. J. Appl. Physiol 1986; 61;2162-2167.
 
6) Ritz,P., Cole T.J., Couet C.:Precision of DLW energy expenditure measurements contribution of natural abundance variations. Am. J. Physiol 1996; 270;E164-E169.
PubMed
7) Moon J. K.:Whole body, human respiration calorimetry. Ph.D. thesis at University of Texas Austin 1991. (富士医科産業 中島茂氏より提供)
 
8) Benedict F.G., Carpenter T.M.:The metabolism and energy transformations of healthy man during rest. The Carnegie Institute, Washington, D.C. (1910). (quoted from Borshein, E.& Bahr, R. Effect of exercise intensity, duration and mode on post-exercise oxygen consumption. Sports Med 2003;33;1039.)
 
9) Tokuyama K.,Sato M.,Ogata H.et al:Improved transient response of wholeody indirect calorimeter by deconvolution. Japanese Journal of Physicalitness and Sports Medicine 2007;56;315-326.
 
10) FAO/WHO/UNUの専門委員会報告, 1985.
 
11) Zhang K.,Sun M.,Warner P.et al:Sleeping metabolic rate in relation to bodyass index and body composition. Int J Obesity 2002;26;376.
 
12) Kumahara H., Yoshioka M.,Yoshitake Y. et al:The difference between theasal metabolic rate and the sleeping metabolic rate in Japanese. J Nutr Sciitaminol 2004;50;441-445.
 
13) Ganpule A.A.,Tanaka S.,Ishikawa-Takata K.et al:Interindividual variabilityn sleeping metabolic rate in Japanese subjects. Eur. J. Clin. Nutr. (inress, 2007)
 
14) Boyle P.J.,Scott J.C.,Krentz A.J.et al:Diminished brain glucose metabolisms a significant determinant for falling rate of systemic glucose utilizationuring sleep in normal humans. J Clin Invest 1994;93;529-535.
 
15) Kelley D.E., Mandarino L.J.:Fuel selection in human skeletal muscle innsulin resistance:a reexamination. Diabetes 2000;49;677.
PubMed
16) Elia M.:Organ and tissue contribution to metabolic rate.In "Energy Metabolism and Cellular Corollaries"(edited by Kinney, J.M.& Tucker H.N.) pp61-79, Raven Press, New York, 1992.
 
17) Ravussin E., Lillioja S.,Knowler W.:Reduced rate of energy expenditure as risk factor for body weight gain. New Engl J Med 1988;318;467-472.
PubMed
18) Levine, J.A.:Nonexercise activity thermogenesis (NEAT):environment andiology. Am J Physiol 2004;286;E675-E685.
 
19) de Boer J.O., van Es A.J., van Raaij J.M. et al:Energy requirements andnergy expenditure of lean and overweight women, measured by indirectalorimetry. Am J Clin Nutr 1987;46;13-21.
PubMed
20) Heymsfield S.B., Harp J.B., Reitman M.L. et al:Why do obese patients not lose more weight when treated with low-calorie diets? A mechanistic perspective Am J Clin Nutr 2007;85;346-354.
 
21) Dolezal B.A., Potteiger J.A., Jacobsen D.J. et al:Muscle damage and restingetabolic rate after resistance exercise with an eccentric overload.Med Sciports Exerc 2000;32;1202-1207.
PubMed
22) Speakman J.R.,Selman,C.:Physical activity and resting metabolic rate.Procutr Soc 2003;62;621-634.
PubMed
23) Melanson E.,Donahoo W.T.,Grunwald G.K.,et al:Changes in 24 h substratexidation in older and younger men in response to exercise.J Appl Physiol(inress 2007)
PubMed
24) 平成9年国民栄養調査
 
25) Sungsoo C., Marion D., Brown C.J.P. et al:The effect of breakfast type on total daily energy intake and body mass index:Results from the third National Health and Nutrition Examination Survey (NHANES III). J Am Col Nutr 2003;22;296-302.
 
26) 中村和照, 宮下政司, 緒形ひとみほか:就寝直前の夕食が睡眠時のエネルギー代謝に及ぼす影響. 肥満研究 2007; 56; 250-255.
 
27) Wolever T., Jenkins D.,Ocana A.M.et al:Second meal effect:low-glycemic-index foods eaten at dinner improve subsequent breakfast glycemic response. Am J Clin Nutr 1988;48;1041-1047.
PubMed
28) Hofstetter A., Schutz Y., Jeruier E.et al:Increased 24-hour energy expendituren cigarette smokers. New Engl J Med 1986;314;79-82.
 
29) Dulloo A.G. Duret C., Rohrer D. et al:Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans. Am J Clin Nutr 1999;70;1040-1045.
 
30) Diepvens K.,Westertero K.R.,Westerterp-Plantenga M.S.:Obesity and thermogenesis related to the consumption of caffeine, ephedrine, capsaicin, and green tea. Am J Physiol 2007;292;R77-R85.
 
31) Kim M.-S. et al:Anti-obesity effects of a-lipoic acid mediated by suppression of hypothalamic AMP-activated protein kinase. Neture Medicine 2005;10; 727-7333.
 
32) Watanabe M., Houten S.M., Mataki C. et al:Bile acids induces energyxpenditure by promoting intracellular thyroid hormone activation. Nature 2006;439;484.
PubMed
33) Kobayashi M, Ikegami H., Fujisawa T. et al:Prevention and treatment ofbesity, insulin resistance, and diabetes by bile acid-binding resin. Diabetes 2007;56;239.
PubMed
34) Lagouge M. et al:Resveratrol improves mitochondrial function and protectsgainst metabolic disease by acivating SIRT1 and PGC-1a. Cell 2006;127; 1109-1122.
 
35) Van Es A.J.H.,Vogt J.E.,Niessen C.et al:Human energy metabolism below,ear and above equibrium. Br J Nutr 1984;52;429-442.
 
36) Dauncey M.J.:Metabolic effects of altering the 24 h energy intake in man,sing direct and indirect calorimetry. Br J Nutr 1980;43;257-269.
 
37) Plasqui G., Kester A.D.M., Westerterp K.R.:Seasonal variation in sleeping metabolic rate, thyroid activity, and leptin. Am J Physiol 2003;285;E338-E343.
 
38) Ferrannini E.:The theoretical bases of indirect calorimetry. Metabolism 1988;37;287-301.
PubMed
39) Brown D., Cole T.J., Dauncey M.J. et al:Analysis of gaseous exchange inpen-circuit indirect calorimetry.Medical Biological Engineering & Computing 1984;22;333-338.
 
40) Rumpler W.V., Seale J.L., Conway J.M. et al:Repeatability of 24-h energyxpenditure measurements in humans by indirect calorimetry.Am J Clin Nutr 1990;51;147-152.
PubMed
41) Seale J.L., Rumpler W.V., Moe P.W.:Description of a direct-indirect roomsized calorimeter. Am J Physiol 1991;260;E306-E320.
PubMed
42) Dauncey M.J.,Murgatoyd P.R.,Cole T.J.:A human calorimeter for the directnd indirect measurement of 24h energy expenditure.Br J Nutr 1978;39;557566.
 
43) Dauncey M.J.:Metabolic effects of altering the 24 h energy intake in man,sing direct and indirect calorimetry. Br J Nutr 1980;43;257-269.
 
44) Charbonnier A., Jones C.D.R., Shutz Y. et al:A whole body transportable indirect calorimeter for human use in the tropics. Eur J Clin Nutr 1990;44; 725-731.
 
45) Hofstetter A., Schutz Y., Jeruier E.et al:Increased 24-hour energy expendituren cigarette smokers. New Engl J Med 1986;314;79-82.
 
46) Hugli O., Schutz Y., Fitting J.-W.:The daily energy expenditure in stablehronic obstructive pulmonary disease.Am J Respir Crit Care Med 1996;153; 294-300.
PubMed
47) Schutz Y.,Bessard T.,Jequier E.:Diet-induced thermogenesis measured over a whole day in obese and nonobese women. Am J Clin Nutr 1984;40;542-552.
 
48) Dulloo A.G., Ismail M.N.,Ryall M. et al:A low-budget and easy-to-operate room respirometer for measuring daily energy expenditure in man. Am J Clin Nutr 1988;48;1367-1374.
 
49) Schoffelen P.F., Westerterp M.K.R., Saris W.H.M. et al:A dual-respiration chamber system with automated calibration. J Appl Physiol 2072;83;2064-1997.
 
50) Ravussin E., Lillioja S., Anderson T.E. et al:Determination of 24-hournergy expenditure in man:Methods and results using a respiratory chamber. Clin Invest 1986;78;1568-1578.
PubMed
51) Sun M.,Reed G.W.,Hill J.O.:Modification of a whole room indirect calorimeteror measurement of rapid changes in energy expenditure. J Appl Physiol 1994;76;2686-2691.
PubMed
52) de Jonge L.,Nguyen T.,Smith S.R.et al:Prediction of energy expenditure in whole body indirect calorimeter at both low and high levels of physicalctivity. Int J Obesity 2001;25;929-934.
 
53) White M.D., Bouchard G., Buemann B. et al:Reproducibility of 24-h energy expenditure and macronutrient oxidation rates in an indirect calorimeter. J Appl Physiol 1996;80;133-139.
 
54) Henning B., Lofgren R., Sjostrom L.:Chamber for indirect calorimetry withmproved transient response. Biomedical Engineering 1996;34;207-212.
 
55) Murgatroyd P.R., Shetty P.S., Prentice A.M. et al:Techniques for the measurement of human energy expenditure:a practical guide. Int J Obesity 1993; 17;549-568.
 
56) Withers R.T., Gore C.J., Mackay M.H. et al:Some aspects of metabolismollowing 35 km road run. Eur J Appl Physiol 1991;63;436-443.
 
57) Iwayama K., Miyashita M., Tokuyama K.:Changes in substrate oxidationersist overnight after the marathon race. Japanese Journal of Physicalitness and Sports Medicine 2008;57;163-168.
 

第3章 肥満・メタボリックシンドローム予防・改善における運動の役割

P.59 掲載の参考文献
1) Matsumoto T.,Miyawaki T.,Ue H.et al:Autonomic responsiveness to acuteold exposure in obese and non-obese young women. Int J Obesity 1999;23; 793-800.
 
2) Bray G.A.:Obesity, a disorder of nutrient partitioning:The MONA LISAypothesis. J Nutr 1991;121;1146-1162.
PubMed
3) 森谷敏夫, 林 達也, 枡田 出ほか: 運動前後における脳波, 自律神経, 血圧・循環調節ホルモンの変化. 運動生化学 1997; 9; 112-115.
 
4) Amano M.,Kanda T.,Ue H. et al:Exercise training and autonomic nervousystem activity in obese individuals. Med Sci Sports Exer 2001;33;12871291.
 
5) 森谷敏夫: 生活習慣病における運動療法の役割. 日本整形外科スポーツ医学会雑誌 2006; 25; 361-368.
 
6) Moritani T.,Kimura T.,Hamada T.et al:Electrophysiology and Kinesiologyor Health and Disease. J Electromyogr Kinesiol 2005;15;240-255.
 
7) Ue H., Masuda I., Yoshitake Y. et al:Assessment of cardiac autonomicervous activities by means of ECG R-R interval power spectral analysis andardiac depolarization-repolarization process. Ann Noninvasive Electrocardiol 2000;5;336-345.
 
8) Billman G.E.:Cellular mechanisms for ventricular fibrillation.News Physiolci 1992;7;254-259.
 
9) Billman G.E., Hoskins R.S.:Time-series analysis of heart rate variabilityuring submaximal exercise:evidence for reduced cardiac vagal tone innimals susceptible to ventricular fibrillation. Circulation 1989;80;874-880.
 
10) Akselrod S., Gordon D., Ubel F.A. et al:Power spectrum analysis of heartate fluctuation:a quantitative probe of beat-to-beat cardiovascular control.cience 1981;213;220-222.
 
11) 森谷敏夫: 運動による自律神経活動の賦活とその生理学的意義. 糖尿病の食事・運動療法(津田謹輔, 林 達也編集), 文光堂, 2007, p162-168.
 
12) Matumoto T., Miyawaki C., Ue H. et al:Effects of capsaicin-containing yellow curry sauce on sympathetic nervous system activity and diet-induced thermogenesis in lean and obese young women. J Nutr Sci Vitaminol 2000; 46;309-315.
 
13) Matumoto T., Miyawaki C., Ue H. et al:Comparison of thermogenic sympathetic response to food intake between obese and non-obese young women. Obesity Res 2001;9;78-85.
 
14) 森谷敏夫, 永井成美: 運動効果を生かす食品. 血圧 2004; 11; 1297-1302.
Medical*Online
15) Nagai N., Sakane N., Ueno M.L. et al:The-3826A→G variant of the uncoupling protein-1 gene diminishes postprandial thermogenesis after a high-fat meal in healthy boys. J Clin Endocrinol Metabol 2003;88;5661-5667.
 
16) Nagai N., Moritani T.:Effect of physical activity on autonomic nervous system function in lean and obese children. Int J Obesity 2004;28;27-33.
 
17) Nagai N., Hamada T., Kimura T. et al:Moderate physical exercise increases cardiac autonomic nervous system activity in children with low heart rate variability. Child's Nervous System 2004;20;209-214.
 
18) 永井成美, 坂根直樹, 森谷敏夫: 朝食欠食, マクロニュートリエントバランスが若年健常者の食後血糖値, 満腹感, エネルギー消費量, 及び自律神経活動へ及ぼす影響. 糖尿病 2005; 48; 761-770.
 
19) 健康・栄養情報研究会編: 平成15年国民健康・栄養調査報告, 第一出版, 2005, p.320, 付録p.3
 
20) Kimura T., Matsumoto T., Akiyoshi M. et al:Body fat and blood lipids inostmenopausal women are related to resting autonomic nervous systemctivity. Eur J Appl Physiol 2006;97;542-547.
PubMed
21) Matsumoto T., Ushiroyama T., Morimura N. et al:Autonomic nervousystem activity in the late luteal phase of eumenorrheic women with premenstrualymptomatology. J Psychosomat Obst Gynecol 2006;27(3);131-139.
 
22) 松本珠希, 後山尚久, 木村哲也ら: 自律神経活動から評価した更年期外来における心理療法の臨床効果. 日本更年期医学会雑誌 2007; 15; 135-145.
 
23) Matumoto T., Miyawaki C., Ue H. et al:Effects of capsaicin-containing yellow curry sauce on sympathetic nervous system activity and diet-induced thermogenesis in lean and obese young women. J Nutr Sci Vitaminol 2000; 46;309-315.
 
24) Matumoto T., Miyawaki C., Ue H. et al:Comparison of thermogenic sympathetic response to food intake between obese and non-obese young women. Obesity Res 2001;9;78-85.
 
25) Matsumoto T., Miyatsuji A., Miyawaki T. et al:A potential associationetween endogenous leptin and sympatho-vagal activities in young obeseapanese women. Am J Human Biol 2003;15;8-15.
 
26) Nagai N., Matsumoto T., Kita H. et al:Interrelationship of the Autonomicervous System Activity and the State and Development of Obesity inapanese School Children. Obesity Res 2003;11;25-32.
 
27) 永井成美, 森谷敏夫, 坂根直樹ほか: 香辛料辛味成分が小児の食事誘発性熱産生, 満腹感, 及び交感神経活動へ及ぼす影響. 肥満研究 2003; 9; 52-59.
 
28) Nagai N., Sakane N., Hamada T. et al:The effect of a high-carbohydrateeal on postprandial thermogenesis and sympathetic nervous system activityn boys with a recent onset of obesity. Metabolism 2005;54;430-438.
 
29) Nagai N.,Sakane N.,Moritani T.:Metabolic responses to high-fat or low-fateals and association with autonomic nervous system activity. J Nutr Sciitaminol 2005;51;355-360.
 
30) Shihara N.,Yasuda K.,Moritani T.et al:The association between Trp64Argutation of the s3-adrenergic receptor and autonomic nervous system activity. Clin Endocrinol Metab 1999;84;1623-1627.
 
31) Shihara N., Yasuda K., Moritani T. et al:Cooperative effect of polymorphisms of uncoupling protein 1 and β3-adrenergic receptor genes on autonomic nervous system activity. Int J Obesity 2001;25;761-766.
 
32) Nagai N., Sakane N., Ueno M.L. et al:The-3826A→G variant of the uncoupling protein-1 gene diminishes postprandial thermogenesis after a high-fat meal in healthy boys. J Clin Endocrinol Metab 2003;88;5661-5667.
 
33) Shibata M.,Moritani T.,Miyawaki T.et al:Exercise prescription based uponardiac vagal activity for middle-aged obese women.Int J Obesity 2002;26; 1356-1362.
 
34) Nagai N., Moritani T.:Effect of physical activity on autonomic nervous system function in lean and obese children. Int J Obes 2004;28;27-33.
 
35) Nagai N., Hamada T., Kimura T. et al:Moderate physical exercise increases cardiac autonomic nervous system activity in children with low heart rate variability. Child's Nerv Syst 2004;20;209-214.
 
36) 浅野勝巳(訳): 栄養と身体作業. 運動生理学 大修館書店; 1985; p.384.
 
37) American College of Sports Medicine:Position stand on the recommended quantity and quality of exercise for developing and maintaining cardiorespiratory muscular fitness in healthy adults. Med Sci Sports Exerc 1990;22;265-274.
PubMed
38) Cotman C.W.,Berchtold N.C.:Exercise:a behavioral intervention to enhancerain health and plasticity. Trends Neurosci 25;295-301;2002.
 
39) Cotman C.W.,Engesser-Cesar C.:Exercise enhances and protects brain function.xerc Sport Sci Rev 30;75-79;2002.
 
40) Pedersen B.K., Fischer C.P.:Beneficial health effects of exercise-the role ofL-6 as a myokine. Trends Pharmacol Sci 2007;28(4);152-156.
 
41) Hamada T.,Sasaki H.,Hayashi T.et al:Enhancement of whole body glucoseptake during and after low frequency electrical stimulation of humankeletal muscles. J Appl Physiol 2003;94;2107-2112.
PubMed
42) Hamada T., Hayashi T., Kimura T. et al:Electrical stimulation of humanower extremities enhances energy consumption,carbohydrate oxidation,andhole body glucose uptake. J Appl Physiol 2004;96;911-916.
PubMed
43) Hamada T., Kimura T., Moritani T.:Selective fatigue of fast motor unitsfter electrically elicited muscle contractions.J Electromyogr Kinesiol 2004; 14;531-538.
PubMed
44) 浜田 拓, 林 達也, 森谷敏夫: 筋電気刺激(EMS)を利用した生活習慣病改善の可能性. BME 2003;16;35-41.
 

第4章 褐色脂肪と肥満・メタボリックシンドローム: 実験動物からヒトへ

P.78 掲載の参考文献
1) Cannon B., Nedergaard J.:Brown adipose tissue:function and physiologicalignificance. Physiol Rev 2004;84(1):277-359.
PubMed
2) Cinti S.:The adipose organ.Prostaglandins Leukot Essent Fatty Acids 2005; 73(1):9-15.
PubMed
3) Lowell B.B., Spiegelman B.M.:Towards a molecular understanding ofdaptive thermogenesis. Nature 2000;404(6778):652-60.
PubMed
4) Nedergaard J., Golozoubova V., Matthias A. et al:UCP1:the only proteinble to mediate adaptive non-shivering thermogenesis and metabolic inefficiency.iochim Biophys Acta 2001;1504(1):82-106.
PubMed
5) Garlid K.D., Jaburek M., Jezek P.:The mechanism of proton transportediated by mitochondrial uncoupling proteins.FEBS Lett 1998;438(1-2):104.
 
6) Cassard-Doulcier A.M., Gelly C., Fox N. et al:Tissue-specific and beta-adrenergic regulation of the mitochondrial uncoupling protein gene:control by cis-acting elements in the 5'-flanking region. Mol Endocrinol 1993;7(4):497-506.
PubMed
7) Puigserver P.,Wu Z.,Park C.W.et al:A cold-inducible coactivator of nucleareceptors linked to adaptive thermogenesis. Cell 1998;92(6):829-39.
PubMed
8) Lin J.,Wu P.H.,Tarr PT.et al:Defects in adaptive energy metabolism withNS-linked hyperactivity in PGC-1alpha null mice.Cell 2004;119(1):121-35.
 
9) Tiraby C., Tavernier G., Lefort C. et al:Acquirement of brown fat celleatures by human white adipocytes. J Biol Chem 2003;278(35):33370-6.
PubMed
10) de Jesus L.A., Carvalho S.D., Ribeiro M.O. et al:The type 2 iodothyronineeiodinase is essential for adaptive thermogenesis in brown adipose tissue. Jlin Invest 2001;108(9):1379-85.
 
11) Watanabe M.,Houten S.M.,Mataki C.et al:Bile acids induce energy expenditurey promoting intracellular thyroid hormone activation. Nature 2006; 439(7075):484-9.
PubMed
12) Cinti S.:The role of brown adipose tissue in human obesity. Nutr Metabardiovasc Dis 2006;16(8):569-74.
PubMed
13) Thomas S.A.,Palmiter R.D.:Thermoregulatory and metabolic phenotypes ofice lacking noradrenaline and adrenaline. Nature 1997;387(6628):94-7.
 
14) Bachman E.S., Dhillon H., Zhang C.Y. et al:betaAR signaling required foriet-induced thermogenesis and obesity resistance. Science 2002;297(5582):843-5.
PubMed
15) Jimenez M., Leger B., Canola K. et al:Beta(1)/beta(2)/beta(3)-adrenoceptornockout mice are obese and cold-sensitive but have normal lipolyticesponses to fasting. FEBS Lett 2002;530(1-3):37-40.
PubMed
16) Enerbeck S., Jacobsson A., Simpson E.M. et al:Mice lacking mitochondrial uncoupling protein are cold-sensitive but not obese. Nature 1997;387(6628):90-4.
 
17) Cannon B., Houstek J., Nedergaard J.:Brown adipose tissue. More than anffector of thermogenesis?Ann N Y Acad Sci 1998;856((null)):171-87.
 
18) Okamatsu-Ogura Y., Kitao N., Kimura K. et al:Brown fat UCP1 is notnvolved in the febrile and thermogenic responses to IL-1beta in mice.Am Jhysiol Endocrinol Metab 2007;292(4):E1135-9.
PubMed
19) Lowell B.B., S-Susulic V., Hamann A. et al:Development of obesity inransgenic mice after genetic ablation of brown adipose tissue.Nature 1993; 366(6457):740-2.
PubMed
20) Li B., Nolte L.A., Ju J.S. et al:Skeletal muscle respiratory uncoupling preventsiet-induced obesity and insulin resistance in mice. Nat Med 2000; 6(10):1115-20.
PubMed
21) Kopecky J., Clarke G., Enerbeck S. et al:Expression of the mitochondrialncoupling protein gene from the aP2 gene promoter prevents genetic obesity. Clin Invest 1995;96(6):2914-23.
 
22) Stefl B., Janovska A., Hodny Z. et al:Brown fat is essential for cold-induced thermogenesis but not for obesity resistance in aP2-Ucp mice. Am J Physiol 1998;274(3 Pt 1):E527-33.
PubMed
23) Ishigaki Y.,Katagiri H.,Yamada T.et al:Dissipating excess energy stored inhe liver is a potential treatment strategy for diabetes associated with obesity.iabetes 2005;54(2):322-32.
 
24) Nagase I.,Yoshida T.,Kumamoto K.et al:Expression of uncoupling proteinn skeletal muscle and white fat of obese mice treated with thermogenic beta 3-adrenergic agonist. J Clin Invest 1996;97(12):2898-904.
 
25) Umekawa T., Yoshida T., Sakane N. et al:Anti-obesity and anti-diabeticffects of CL316,243, a highly specific beta 3-adrenoceptor agonist,in Otsukaong-Evans Tokushima Fatty rats:induction of uncoupling protein andctivation of glucose transporter 4 in white fat. Eur J Endocrinol 1997; 136(4):429-37.
PubMed
26) Inokuma K., Okamatsu-Ogura Y., Omachi A. et al:Indispensable role ofitochondrial UCP1 for antiobesity effect of beta3-adrenergic stimulation.m J Physiol Endocrinol Metab 2006;290(5):E1014-21.
 
27) Okamatsu-Ogura Y., Uozumi A., Toda C. et al:Uncoupling protein 1 contributes to fat-reducing effect of leptin. Obes Res Clin. Prac 2007;1:233-41.
 
28) Yamada T.,Katagiri H., Ishigaki Y. et al:Signals from intra-abdominal fatodulate insulin and leptin sensitivity through different mechanisms:neuronalnvolvement in food-intake regulation. Cell Metab 2006;3(3):223-9.
PubMed
29) Shimizu Y., Nikami H., Tsukazaki K. et al:Increased expression of glucose transporter GLUT-4 in brown adipose tissue of fasted rats after cold exposure. Am J Physiol 1993;264(6 Pt 1):E890-5.
 
30) Shimizu Y., Nikami H., Saito M.:Sympathetic activation of glucose utilizationn brown adipose tissue in rats.J Biochem (Tokyo) 1991;110(5):688-92.
PubMed
31) Inokuma K., Ogura-Okamatsu Y., Toda C. et al:Uncoupling protein 1 isecessary for norepinephrine-induced glucose utilization in brown adiposeissue. Diabetes 2005;54(5):1385-91.
PubMed
32) Cassard A.M., Bouillaud F., Mattei M.G. et al:Human uncoupling proteinene:structure,comparison with rat gene,and assignment to the long arm ofhromosome 4. J Cell Biochem 1990;43(3):255-64.
 
33) Nedergaard J., Bengtsson T., Cannon B.:Unexpected evidence for activerown adipose tissue in adult humans.Am J Physiol Endocrinol Metab 2007; 293(2):E444-52.
PubMed
34) Ricquier D., Nechad M., Mory G.:Ultrastructural and biochemical characterization of human brown adipose tissue in pheochromocytoma. J Clin Endocrinol Metab 1982;54(4):803-7.
PubMed
35) Lean M.E., James W.P., Jennings G. et al:Brown adipose tissue in patientsith phaeochromocytoma. Int J Obes 1986;10(3):219-27.
PubMed
36) Cassard A.M., Bouillaud F., Mattei M.G. et al:Human uncoupling proteinene:structure,comparison with rat gene,and assignment to the long arm ofhromosome 4. J Cell Biochem 1990;43(3):255-64.
 
37) Garruti G., Ricquier D.:Analysis of uncoupling protein and its mRNA indipose tissue deposits of adult humans.Int J Obes Relat Metab Disord 1992; 16(5):383-90.
PubMed
38) Kortelainen M.L.,Pelletier G.,Ricquier D.et al:Immunohistochemical detectionf human brown adipose tissue uncoupling protein in an autopsy series. Histochem Cytochem 1993;41(5):759-64.
 
39) Sasaki N., Uchida E., Niiyama M. et al:Anti-obesity effects of selectivegonists to beta-adrenergic receptor in dogs. II. Recruitment of thermogenicrown adipocytes and reduction of adiposity after chronic treatment with aeta3-adrenergic agonist. J Vet Med Sci 1998;60:465-9.
PubMed
40) Omachi A.,Ishioka K.,Uozumi A et al:Beta3-adrenoceptor agonist AJ-9677educes body fat in obese beagles. Res Vet Sci 2007;83:5-11.
 
41) Omachi A., Matsushita Y., Kimura K. et al:Role of uncoupling protein 1 in the anti-obesity effect of beta3-adrenergic agonist in the dog. Res Vet Sci 2007 in press.
 
42) Engel H., Steinert H., Buck A. et al:Whole-body PET:physiological andrtifactual fluorodeoxyglucose accumulations.J Nucl Med 1996;37(3):441-6.
PubMed
43) Barrington S.F., Maisey M.N. et al:Skeletal muscle uptake of fluorine-18FDG:effect of oral diazepam. J Nucl Med 1996;37(7):1127-9.
PubMed
44) Hany T.F., Gharehpapagh E., Kamel E.M. et al:Brown adipose tissue:aactor to consider in symmetrical tracer uptake in the neck and upper chestegion. Eur J Nucl Med Mol Imaging 2002;29(10):1393-8.
PubMed
45) Yeung H.W., Grewal R.K., Gonen M.et al:Patterns of (18)F-FDG uptake indipose tissue and muscle:a potential source of false-positives for PET. Jucl Med 2003;44(11):1789-96.
 
46) Fukuchi K., Tatsumi M., Ishida Y. et al:Radionuclide imaging metabolicctivity of brown adipose tissue in a patient with pheochromocytoma. Explin Endocrinol Diabetes 2004;112(10):601-3.
 
47) Parysow O.,Mollerach A.M.,Jager V.et al:Low-dose oral propranolol couldeduce brown adipose tissue F-18 FDG uptake in patients undergoing PETcans. Clin Nucl Med 2007;32(5):351-7.
PubMed
48) Almind K., Manieri M., Sivitz W.I. et al:Ectopic brown adipose tissue inuscle provides a mechanism for differences in risk of metabolic syndrome inice. Proc Natl Acad Sci USA 2007;104(7):2366-71.
 

第II編 エネルギー・脂質代謝調節の分子機構

P.105 掲載の参考文献
1) Cahill G.F.Jr.:Starvation in man. N Engl J Med 1970;282;668-675.
 
2) Randle P.J., Garland P.B.,Hales C.N.et al:The glucose fatty-acid cycle.Itsole in insulin sensitivity and the metabolic disturbances of diabetes mellitus.ancet 1963;1;785-789.
 
3) Kamei Y.,Miura S., Suzuki M. et al:Skeletal muscle FOXO1 (FKHR)transgenicice have less skeletal muscle mass, down-regulated Type I (slowwitch/red muscle) fiber genes, and impaired glycemic control. J Biol Chem 2004;279;41114-41123.
 
4) Southgate R.J.,Neill B., Prelovsek O.et al:FOXO1 regulates the expressionf 4E-BP1 and inhibits mTOR signaling in mammalian skeletal muscle. Jiol Chem 2007;282;21176-21186.
 
5) 江崎 治, 亀井康富:サルコペニアおよび廃用性萎縮への研究戦略と目標. 日本医師会雑誌. 2004;132;977-979.
 
6) Drenick E.J.:Clinical disorders of fluid and electrolyte metabolism. New York:McGraw Hill, 1980,p1481-1501.
 
7) Hood V.L.:Fluids and electrolytes. Philadelphia:WS Sauders, 1986, p712
 
8) Nilsson L.H.:Liver glycogen content in man in the postabsorptive state.cand J Clin Lab Invest 1973;32;317-323.
 
9) アリソンS.P.:医師のための栄養学. ダノン健康・栄養普及協会, 1999, p 83-85.
 
10) Nisoli E.,Tonello C.,Cardile A.et al:Calorie restriction promotes mitochondrialiogenesis by inducing the expression of eNOS. Science 2005;310;314317.
 
11) Landsberg L.,Young J.B.:Fasting,feeding and regulation of the sympatheticervous system. N Engl J Med 1978;298;1295-1301.
PubMed
12) Garrow J.S., Webster J.D.:Effects on weight and metabolic rate of obeseomen of a 3.4 MJ (800kcal) diet. Lancet 1989;1;1429-1431.
 
13) Minghelli G., Schutz Y., Charbonnier A. et al:Twenty-four-hour energy expenditure and basal metabolic rate measured in a whole-body indirect calorimeter in Gambian men. Am J Clin Nutr 1990;51;563-570.
 
14) Shetty P.S.:Nutr Res Rev 1990;3;49-74.
PubMed
15) de Lange P., Farina P., Moreno M. et al:Sequential changes in the signalransduction responses of skeletal muscle following food deprivation.FASEB 2006;20;2579-2581.
PubMed
16) Furuyama T., Kitayama K., Yamashita H. et al:Forkhead transcriptionactor FOXO1 (FKHR)-dependent induction of PDK4 gene expression inkeletal muscle during energy deprivation. Biochem J 2003;375;365-371.
PubMed
17) Kamei Y., Mizukami J., Miura S. et al:A forkhead transcription factorKHR up-regulates lipoprotein lipase expression in skeletal muscle. FEBSett 2003;536;232-236.
 
18) Furuyama T.,Yamashita H.,Kitayama K.et al:Effects of aging and caloricestriction on the gene expression of Foxo1,3,and 4(FKHR, FKHRL1,andFX) in the rat skeletal muscles. Microsc Res Tech 2002;59;331-334.
PubMed
19) Bizeau M.E., MacLean P.S., Johnson G.C. et al:Skeletal muscle sterol regulatory element binding protein-1c decreases with food deprivation and increases with feeding in rats. J Nutr 2003;133;1781-1792.
 
20) Martin I.K., Katz A., Wahren J.:Splanchnic and muscle metabolism duringxercise in NIDDM patients. Am J Physiol 1995;269;E583-E590.
PubMed
21) Wolfe R.R.,Klein S.,Carraro F.et al:Role of triglyceride-fatty acid cycle inontrolling fat metabolism in humans during and after exercise.Am J Physiol 1990;258;E382-E389.
PubMed
22) 江崎 治, 三浦進司:メタボリックシンドロームにおける運動療法の分子基盤. 実験医学 2007;25;(増刊) 2441-2447.
 
23) Ahlborg G., Felig P., Hagenfeldt L. et al:Substrate turnover during prolonged exercise in man. Splanchnic and leg metabolism of glucose, free fatty acids, and amino acids. J Clin Invest 1974;53;1080-1090.
PubMed
24) Romijn J.A.,Coyle E.F.,Sidossis L.S.et al:Regulation of endogenous fat andarbohydrate metabolism in relation to exercise intensity and duration.Am Jhysiol 1993;265;E380-E391.
PubMed
25) Romijn J.A., Coyle E.F., Sidossis L.S. et al:Relationship between fatty acidelivery and fatty acid oxidation during strenuous exercise. J Appl Physiol 1995;79;1939-1945.
PubMed
26) van Loon L.J., Greenhaff P.L., Constantin-Teodosiu D. et al:The effects ofncreasing exercise intensity on muscle fuel utilisation in humans. J Physiol 2001;536;295-304.
PubMed
27) Starritt E.C., Howlett R.A., Heigenhauser G.J. et al:Sensitivity of CPT I toalonyl-CoA in trained and untrained human skeletal muscle.Am J Physiolndocrinol Metab 2000;278;E462-E468.
 
28) Achten J., Jeukendrup A.E.:Optimizing fat oxidation through exercise andiet. Nutrition 2004;20;716-727.
PubMed
29) Turcotte L.P., Richter E.A., Kiens B.:Increased plasma FFA uptake andxidation during prolonged exercise in trained vs. untrained humans. Am Jhysiol 1992;262;E791-E799.
PubMed
30) Ohkawara K.,Tanaka S.,Miyachi M.et al:A dose-response relation betweenerobic exercise and visceral fat reduction:systematic review of clinicalrials. Int J Obes (Lond)2007;31(12);1786-1797.
 
31) Winder W.W.:Energy-sensing and signaling by AMP-activated protein kinase in skeletal muscle. J Appl Physiol 2001;91;1017-1028.
PubMed
32) Miura S., Kamei Y., Ezaki O.:AMP-Activated Protein Kinase in Skeletal Muscle Is Required for a Reduction of Fat Mass by Exercise Training. Diabetes 2006;55 Suppl;A241.
 
33) 江崎 治, 三浦進司:AMPキナーゼ. Clinical Neuroscience 2006;24;929-931.
 
34) Hickner R.C., Racette S.B., Binder E.F. et al:Suppression of whole body and regional lipolysis by insulin:effects of obesity and exercise. J Clin Endocrinol Metab 1990;84:3886-3895.
 
35) Goto M., Terada S., Kato M. et al:cDNA Cloning and mRNA analysis ofGC-1 in epitrochlearis muscle in swimming-exercised rats. Biochem Biophyses Commun. 2000;274;350-354.
 
36) Miura S.,Kawanaka K.,Kai Y. et al:An increase in murine skeletal muscleeroxisome proliferator-activated receptor-gamma coactivator-lalpha (PGClalpha)mRNA in response to exercise is mediated by beta-adrenergic receptorctivation. Endocrinology 2007;148;3441-3448.
 
37) Wende A.R., Schaeffer P.J., Parker G.J. et al:A role for the transcriptionaloactivator PGC-l alpha in muscle refueling. J Biol Chem 2007;282;36642-36651.
 
38) Miura S., Tomitsuka E., Kamei Y. et al:Overexpression of peroxisomeroliferator-activated receptor gamma co-activator-1alpha leads to muscletrophy with depletion of ATP. Am J Pathol 2006;169;1129-1139.
PubMed
39) Ross R., Dagnone D., Jones P.J. et al:Reduction in obesity and relatedomorbid conditions after diet-induced weight loss or exercise-inducedeight loss in men.A randomized,controlled trial.Ann Intern Med 2000;133; 92-103.
PubMed
40) Ross R.,Janssen I.,Dawson J.et al:Exercise-induced reduction in obesity andnsulin resistance in women:a randomized controlled trial. Obes Res 2004:12;789-798.
PubMed
41) Racette S.B.,Weiss E.P.,Villareal D.T.et al:One year of caloric restriction inumans:feasibility and effects on body composition and abdominal adiposeissue. J Gerontol A Biol Sci Med Sci 2006;61;943-950.J of Gerontology 2006, 61A;943-950
 
42) Weiss E.P.,Racette S.B.,Villareal D.T.et al:Improvements in glucose tolerancend insulin action induced by increasing energy expenditure or decreasingnergy intake:a randomized controlled trial. Am J Clin Nutr 2006;84; 1033-1042.
PubMed
43) Tokunaga K., Matsuzawa Y., Kotani K. et al:Ideal body weight estimatedrom the body mass index with the lowest morbidity.Int J Obes 1991;15;1-5.
PubMed
44) Tsugane S., Sasaki S., Tsubono Y.:Under-and overweight impact onortality among middle-aged Japanese men and women:a 10-y follow-up ofPHC study cohort I. Int J Obes Relat Metab Disord 2002;26;529-537.
PubMed
45) Takata Y.,Ansai T., Soh I. et al:Association between body mass index andortality in an 80-year-old population. J Am Geriatr Soc 2007;55;913-917.
 
46) 厚生労働省策定:日本人の食事摂取基準2005年版, 第一出版, p 29.
 
47) Ganpule A.A.,Tanaka S.,Ishikawa-Takata K.et al:Interindividual variabilityn sleeping metabolic rate in Japanese subjects.Eur J Clin Nutr 2007;61; 1256-1261.
PubMed
48) Romijn J.A.,Coyle E.F.,Sidossis L.S.et al:Regulation of endogenous fat andarbohydrate metabolism in relation to exercise intensity and duration.Am Jhysiol 1993;265;E380-E391.
PubMed

第6章 AMPキナーゼによる生体エネルギー代謝調節機構

P.124 掲載の参考文献
1) Hardie D.G., Carling D., Carlson M.:The AMP-activated/SNF1 proteininase subfamily:metabolic sensors of the eukaryotic cell? Annu Rev Biochem 1998;67;821-855.
 
2) Winder W.W.:Energy-sensing and signaling by AMP-activated protein kinase in skeletal muscle. J Appl Physiol 2001;91;1017-1028.
PubMed
3) Dolinsky V.W., Dyck J.R.:Role of AMP-activated protein kinase in healthynd diseased hearts.Am.J.Physiol.Heart Circ.Physiol 2006;291;2557-2569.
 
4) Kahn B.B., Alquier. T, Carling D.:Hardie DG.:AMP-activated proteininase:ancient energy gauge provides clues to modern understanding ofetabolism. Cell Metab 2005;1;15-35.
 
5) Suzuki A., Okamoto S., Lee S. et al:Leptin stimulates fatty acid oxidation and PPARα gene expression in mouse C2C12 myoblasts by changing the subcellular localization of the α2 form of AMP-activated protein kinase. Mol Cell Biol 2007;27;4317-4327.
 
6) Alessi D.R., Sakamoto K., Bayascas J.R.:LKB 1-dependent signaling pathways.nnu Rev Biochem 2006;75;137-163.
 
7) Hong S.P., Leiper F.C., Woods A. et al:Activation of yeast Snf1 andammalian AMP-activated protein kinase by upstream kinases. Proc Natlcad Sci USA 2003;100;8839-8843.
PubMed
8) Hawley S.A., Boudeau J., Reid J.L. et al:Complexes between the LKB 1 tumor suppressor, STRAD alpha/beta and MO 25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol 2003;2;28.
 
9) Hardie D.G.,Sakamoto K.:AMPK:a key sensor of fuel and energy status inkeletal muscle. Physiology 2006;21;48-60.
PubMed
10) Hamilton S.R., O'Donnell J.B. Jr, Hammet A. et al:AMP-activated proteininase kinase:detection with recombinant AMPK alpha 1 subunit. Biochemiophys Res Commun 2002;293;892-898.
 
11) Hawley S.A., Pan D.A., Mustard K.J. et al:Calmodulin-dependent proteininase kinase-beta is an alternative upstream kinase for AMP-activatedrotein kinase. Cell Metab 2005;2;9-19.
 
12) Woods A., Dickerson K.,Heath R. et al:Ca??/calmodulin-dependent proteininase kinase-beta acts upstream of AMP-activated protein kinase in mammalianells. Cell Metab 2005;2;21-33.
 
13) Hurley R.L., Anderson K.A., Franzone J.M. et al:The Ca2+/calmodulindependent protein kinase kinases are AMP-activated protein kinase kinases. Trends Biochem Sci 2006;31;13-16.
 
14) Momcilovic, M., Hong S.P., Carlson M.:Mammalian TAK1 activates Snf1rotein kinase in yeast and phosphorylates AMP-activated protein kinase initro. J Biol Chem 2006;281;25336-25343.
 
15) Shibuya H., Yamaguchi K., Shirakabe K. et al:TAB1:an activator of theAK1 MAPKKK in TGF-beta signal transduction. Science 1996;272;1791182.
 
16) Mu J., Brozinick J.T. Jr, Valladares O. et al:A role for AMP-activatedrotein kinase in contraction-and hypoxia-regulated glucose transport inkeletal muscle. Mol Cell 2001;7;1085-1094.
PubMed
17) Fujii N., Hirshman M.F., Kane E.M. et al:AMP-activated protein kinaseα2 activity is not essential for contraction-and hyperosmolarity-induced glucose transport in skeletal muscle. J Biol Chem 2005;280;39033-39041.
 
18) Abu-Elheiga L., Matzuk M.M., Abo-Hashema K.A. et al.:Continuous fattycid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2. Science 2001;291;2613-2616.
PubMed
19) Yamauchi T., Kamon J., Ito Y. et al:Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2007;13;332-339.
 
20) Yamauchi T., Nio Y., Maki T. et al:Targeted disruption of AdipoR1 anddipoR2 causes abrogation of adiponectin binding and metabolic actions.at Med 2007;13;332-339,
PubMed
21) Steinberg G.R., Michell B.J., van Denderen B.J. et al:Tumor necrosis factorlpha-induced skeletal muscle insulin resistance involves suppression of AMPkinase signaling. Cell Metab 2006;4;465-474.
PubMed
22) Jager S., Handschin C., St.-Pierre J. et al:AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1α. Proc Natl Acad Sci 2007;104;12017-12022.
 
23) Morino K, Petersen K.F., Shulman G.I.:Molecular mechanisms of insulinesistance in humans and their potential links with mitochondrial dysfunction.iabetes 2006;55 Suppl 2;S9-S15.
 
24) Banerjee R.R.,Rangwala S.M.,Shapiro J.S.et al:Regulation of fasted bloodlucose by resistin. Science 2004;303;1195-1198.
PubMed
25) Koo S.H., Flechner L., Qi L. et al:The CREB coactivator TORC2 is a keyegulator of fasting glucose metabolism. Nature 2005;437;1109-1111.
PubMed
26) Shaw R.J.,Lamia K.A.,Vasquez D.et al:The kinase LKB1 mediates glucoseomeostasis in liver and therapeutic effects of metformin.Science 2005,310; 1642-1646.
PubMed
27) Shu Y., Sheardown S.A., Brown C. et al:Effect of genetic variation in therganic cation transporter 1 (OCT1)on metformin action.J Clin Invest 2007; 117;1422-1431.
PubMed
28) Minokoshi Y., Kim Y.-B., Odile D. et al:Leptin stimulates fatty acid oxidationy activation of AMP-activated protein kinase. Nature 2002;415;339343.
 
29) Minokoshi Y., Alquier T., Furukawa N. et al:AMP-kinase regulates foodntake by responding to hormonal and nutrient signals in the hypothalamus.ature 2004;428;569-574.
 
30) Minokoshi Y., Haque M.S., Shimazu T.:Microinjection of leptin into theentromedial hypothalamus increases glucose uptake in peripheral tissues inats. Diabetes 1999;48;287-291.
 
31) Haque M.S.,Minokoshi Y.,Hamai M.et al:Role of the sympathetic nervousystem and insulin in enhancing glucose uptake in peripheral tissues afterntrahypothalamic injection of leptin in rats. Diabetes 1999;48;1706-1712.
PubMed
32) Shimomura I., Hammer R.E., Ikemoto S. et al:Leptin reverses insulin resistancend diabetes mellitus in mice with congenital lipodystrophy. Nature 1999;401;73-76.
PubMed
33) Oral E.A.,Simha V.,Ruiz E.et al:Leptin-replacement therapy for lipodystrophy. Engl J Med 2002;346;570-578.
 
34) Ebihara K., Masuzaki H.,Nakao K.:Long-term leptin-replacement therapyor lipoatrophic diabetes. N Engl J Med 2004;19;127-129.
 
35) Tanaka T., Hidaka S., Masuzaki H. et al:Skeletal muscle AMP-activatedrotein kinase phosphorylation parallels metabolic phenotype in leptin transgenicice under dietary modification. Diabetes 2005;54;2365-2374.
PubMed
36) Tanaka T., Masuzaki H., Yasue S. et al:Central melanocortin signalingestores skeletal muscle AMP-activated protein kinase phosphorylation inice fed a high-fat diet. Cell Metab 2007;5;395-402.
 
37) Kim E.K., Miller I., Aja S. et al:C75, a Fatty Acid Synthase Inhibitor,educes Food Intake via Hypothalamic AMP-activated Protein Kinase. Jiol Chem 2004;276;19970-19976.
 
38) Kim M., Park J.Y, Namkoong C. et al:Anti-obesity effects of a-lipoic acidediated by suppression of hypothalamic AMP-activated protein kinase.Nated 2004;10;727-733.
 
39) Andersson U.,Filipsson K.,Abbott C.R.et al:AMP-activated protein kinaselays a role in the control of food intake.J Biol Chem 2004;279;12005-12008.
PubMed
40) Kola B., Hubina E., Tucci S.A. et al:Cannabinoids and ghrelin have bothentral and peripheral metabolic and cardiac effects via AMP-activatedrotein kinase. J Biol Chem 2005;280;25196-25201.
PubMed
41) Xue B., Kahn B.B.:AMPK integrates nutrient and hormonal signals toegulate food intake and energy balance through effects in the hypothalamusnd peripheral tissues. J Physiol;574;73-83.
PubMed
42) Wolfgang M.J.,Lane M.D.:The role of hypothalamic malonyl-CoA in energyomeostasis. J Biol Chem 2006 281;37265-37269.
PubMed
43) He W., Lam T.K., Obici S. et al:Molecular disruption of hypothalamicutrient sensing induces obesity. Nat Neurosci 2006;9;227-233.
PubMed
44) Gao S., Kinsig K.P., Aja S. et al:Leptin activates hypothalamic acetyl-CoAarboxylase to inhibit food intake. Proc Natl Acad Sic 2007;104;1735817363.
 
45) Cota D., Proulx K., Smith K.A. et al:Hypothalamic mTOR signaling regulatesood intake. Science 2006;312;927-930.
PubMed
46) Kubota N.,Yano W.,Kubota T.et al:Adiponectin stimulates AMP-activatedrotein kinase in the hypothalams and increases food intake. Cell Metab 2007;6;1-14.
 

第7章 脂質代謝関連遺伝子の転写制御と肥満

P.137 掲載の参考文献
1) Sato R., Imanaka T., Takatsuki A. et al:Degradation of newly synthesized apolipoprotein B-100 in a pre-Golgi compartment. J Biol Chem 1990;265; 11880-11884.
 
2) Du E.Z., Fleming J.F., Wang S-L. et al:Translation-arrested apolipoprotein ecades proteasome degradation via a sterol-sensitive block in ubiquitinonjugation. J Biol Chem 1999;274;1856-1862.
 
3) Wetterau J.R., Gregg R.E. et al:An MTP inhibitor that normalizes atherogenicipoprotein levelos in WHHL rabbits. Science 1998;282;751-754.
PubMed
4) Hayhurst G.P., Lee Y-H. et al:Hepatocyte nuclear factor 4a (Nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipidomeostasis. Mol Cell Biol 2001;21;1393-4103.
 
5) Hertz R., Mangeheim J., Berman I. et al:Fatty acyl-CoA thioesters are ligands of hepatic nuclear factor-4α. Nature 1998;392;512-516.
 
6) Hirokane H., Nakahara M., Tachibana S. et al:Bile acid reduces the secretionf very low density lipoprotein by repressing microsomal triglycerideransfer protein gene expression mediated by hepatocyte nuclear factor-4. Jiol Chem 2004;279;45685-45692.
 
7) Misawa K., Horiba T., Arimura N. et al:Sterol regulatory element-bindingrotein-2 interacts with hepatocyte nuclear factor-4 to enhance sterolsomerase gene expression in hepatocytes. J Biol Chem 2003;278;3617636185.
PubMed
8) Yamamoto T.,Shimano H.et al:SREBP-1 Interacts with hepatocyte nuclearactor-4a and interferes with PGC-1 recruitment to suppress hepaticluconeogenic genes. J Biol Chem 2004;279;12027-12035.
 
9) Kanayama T., Arito M., So K. et al:Interaction between sterol regulatorylement-binding proteins and liver receptor homolog-1 reciprocally suppressesheir transcriptional activities. J Biol Chem 2007;282;10290-10298,
PubMed
10) Krylova I.N., Sablin E.P. et al:Structural analyses reveal phosphatidylnositols as ligands for the NR5 orphan receptors SF-1 and LRH-1, Cell 2005;120;343-355,
PubMed
11) Li Y.,Choi M.et al:Crystallographic identification and functional characterizationf phospholipids as ligands for the orphan nuclear receptor steroidogenicactor-1. Mol Cell 2005;17;491-502,
PubMed
12) Davis R.A., Miyake J.H. et al:Regulation of cholesterol-7-hydroxylase:AREly missing a SHP. J Lipid Res 2002;43;533-543.
 
13) Delerive P.,Galardi C.M.et al:Identification of liver receptor homolog-1 as novel regulator of apolipoprotein AI gene transcription. Mol Endocrinol 2004;18;2378-2387.
PubMed
14) Iwaki M., Matsuda M. et al:Induction of adiponectin, a fat-derivedntidiabetic and antiatherogenic factor,by nuclear receptors.Diabetes 2003; 52;1655-1663.
PubMed
15) Shimomura I.,Matsuda M. et al:Decreased IRS-2 and increased SREBP-1cead to mixed insulin resistance and sensitivity in livers of lipodystrophic andb/ob Mice. Mol Cell 2000;6;77-86.
 

第8章 胆汁酸によるエネルギー代謝調節機構の分子メカニズムと臨床応用

P.170 掲載の参考文献
1) Stamler J.,Vaccaro O.,Neaton J.D.et al:Diabetes,other risk factors,and 12-r cardiovascular mortality for men screened in the Multiple Risk Factorntervention Trial. Diabetes Care 1993;16;434-44.
 
2) Sone H., Mizuno S., Fujii H. et al:Is the diagnosis of metabolic syndromeseful for predicting cardiovascular disease in asian diabetic patients?Analysisrom the Japan Diabetes Complications Study. Diabetes Care 2005;28; 1463-71.
PubMed
3) Chiang J.Y.:Bile acid regulation of gene expression:roles of nuclear hormoneeceptors. Endocr Rev 2002;23;443-63.
PubMed
4) Javitt N.B.:Bile acid synthesis from cholesterol:regulatory and auxiliaryathways. Faseb J 1994;8;1308-11.
PubMed
5) Axelson M., Sjovall J.:Potential bile acid precursors in plasma--possiblendicators of biosynthetic pathways to cholic and chenodeoxycholic acids inan. J Steroid Biochem 1990;36;631-40.
 
6) Ishibashi S., Schwarz M., Frykman P.K. et al:Disruption of cholesterol 7alpha-hydroxylase gene in mice. I. Postnatal lethality reversed by bile acidnd vitamin supplementation. J Biol Chem 1996;271;18017-23.
PubMed
7) Noshiro M., Usui E., Kawamoto T. et al:Multiple mechanisms regulateircadian expression of the gene for cholesterol 7alpha-hydroxylase(Cyp7a), key enzyme in hepatic bile acid biosynthesis.J Biol Rhythms 2007;22;299311.
 
8) Chiang J.Y., Stroup D.:Identification and characterization of a putative bilecid-responsive element in cholesterol 7 alpha-hydroxylase gene promoter.Jiol Chem 1994;269;17502-7.
 
9) Stroup D., Crestani M., Chiang J.Y.:Orphan receptors chicken ovalbuminpstream promoter transcription factorII(COUP-TFII)and retinoid Xeceptor(RXR)activate and bind the rat cholesterol 7alpha-hydroxylase geneCYP7A). J Biol Chem 1997;272;9833-9.
 
10) Forman B.M.,Goode E.,Chen J.et al:Identification of a nuclear receptor thats activated by farnesol metabolites. Cell 1995;81;687-93.
 
11) Makishima M., Okamoto A.Y., Repa J.J. et al:Identification of a nucleareceptor for bile acids. Science 1999;284;1362-5.
PubMed
12) Parks D.J., Blanchard S.G.,Bledsoe RK.et al:Bile acids:natural ligands forn orphan nuclear receptor. Science 1999;284;1365-8.
 
13) Wang H.,Chen J.,Hollister K.et al:Endogenous bile acids are ligands for theuclear receptor FXR/BAR. Mol Cell 1999;3;543-53.
 
14) Lu T.T.,Makishima M.,Repa J.J.et al:Molecular basis for feedback regulationf bile acid synthesis by nuclear receptors. Mol Cell 2000;6;507-15.
PubMed
15) Brendel C., Schoonjans K., Botrugno O.A. et al:The small heterodimerartner interacts with the liver X receptor alpha and represses its transcriptionalctivity. Mol Endocrinol 2002;16;2065-76.
PubMed
16) Wang L., Lee Y.K., Bundman D. et al:Redundant pathways for negativeeedback regulation of bile acid production. Dev Cell 2002;2;721-31.
PubMed
17) Holt J.A., Luo G., Billin A.N. et al:Definition of a novel growth factordependent signal cascade for the suppression of bile acid biosynthesis.Genesev 2003;17;1581-91.
PubMed
18) Inagaki T., Choi M., Moschetta A. et al:Fibroblast growth factor 15 functionss an enterohepatic signal to regulate bile acid homeostasis.Cell Metab 2005;2;217-25.
 
19) Davis R.A., Miyake J.H., Hui T.Y. et al:Regulation of cholesterol-7alphahydroxylase:BAREly missing a SHP. J Lipid Res 2002;43;533-43.
 
20) Miyake J.H., Wang S.L., Davis R.A.:Bile acid induction of cytokine expressiony macrophages correlates with repression of hepatic cholesterol 7alphahydroxylase. J Biol Chem 2000;275;21805-8.
PubMed
21) De Fabiani E., Mitro N., Anzulovich A.C. et al:The negative effects of bilecids and tumor necrosis factor-alpha on the transcription of cholesterol 7alpha-hydroxylase gene(CYP7A1)converge to hepatic nuclear factor-4:novel mechanism of feedback regulation of bile acid synthesis mediated byuclear receptors. J Biol Chem 2001;276;30708-16.
PubMed
22) Gupta S.,Stravitz R.T.,Dent P.et al:Down-regulation of cholesterol 7alphahydroxylase(CYP7A1)gene expression by bile acids in primary rat hepatocytess mediated by the c-Jun N-terminal kinase pathway.J Biol Chem 2001;276;15816-22.
 
23) Li T.,Chiang J.Y.:Mechanism of rifampicin and pregnane X receptor inhibitionf human cholesterol 7 alpha-hydroxylase gene transcription. Am Jhysiol Gastrointest Liver Physiol 2005;288;G74-84.
PubMed
24) Kalaany N.Y.,Mangelsdorf D.J.:LXRS and FXR:the yin and yang of cholesterolnd fat metabolism. Annu Rev Physiol 2006;68;159-91.
PubMed
25) Lee F.Y.,Lee H.,Hubbert M.L.et al:FXR,a multipurpose nuclear receptor.rends Biochem Sci 2006;31;572-80.
 
26) Houten S.M., Watanabe M., Auwerx J.:Endocrine functions of bile acids.mbo J 2006;25;1419-25.
 
27) Ananthanarayanan M., Balasubramanian N., Makishima M. et al:Humanile salt export pump promoter is transactivated by the farnesoid X receptor/ile acid receptor. J Biol Chem 2001;276;28857-65.
 
28) Chen F., Ma L., Dawson P.A. et al:Liver receptor homologue-1 mediatespecies-and cell line-specific bile acid-dependent negative feedback regulationf the apical sodium-dependent bile acid transporter.J Biol Chem 2003; 278;19909-16.
PubMed
29) Grober J., Zaghini I., Fujii H. et al:Identification of a bile acid-responsivelement in the human ileal bile acid-binding protein gene.Involvement of thearnesoid X receptor/9-cis-retinoic acid receptor heterodimer. J Biol Chem 1999;274;29749-54.
PubMed
30) Landrier J.F.,Eloranta J.J.,Vavricka S.R.et al:The nuclear receptor for bilecids,FXR,transactivates human organic solute transporter-alpha and-betaenes. Am J Physiol Gastrointest Liver Physiol 2006;290;G476-85.
PubMed
31) Qiao L., Han S.I., Fang Y. et al:Bile acid regulation of C/EBPbeta, CREB,nd c-Jun function, via the extracellular signal-regulated kinase and c-JunH2-terminal kinase pathways, modulates the apoptotic response of hepatocytes.ol Cell Biol 2003;23;3052-66.
 
32) Kawamata Y., Fujii R., Hosoya M. et al:A G protein-coupled receptoresponsive to bile acids. J Biol Chem 2003;278;9435-40.
 
33) Maruyama T.,Miyamoto Y.,Nakamura T.et al:Identification of membranetype receptor for bile acids (M-BAR). Biochem Biophys Res Commun 2002;298;714-9.
PubMed
34) Ho K.J.:Circadian distribution of bile acid in the enterohepatic circulatoryystem in hamsters. J Lipid Res 1976;17;600-4.
PubMed
35) Engelking L.R., Dasher C.A., Hirschowitz B.I.:Within-day fluctuations inerum bile-acid concentrations among normal control subjects and patientsith hepatic disease. Am J Clin Pathol 1980;73;196-201.
PubMed
36) Everson G.T.:Steady-state kinetics of serum bile acids in healthy human subjects:single and dual isotope techniques using stable isotopes and mass spectrometry. J Lipid Res 1987;28;238-52.
PubMed
37) Zhang Y., Kast-Woelbern H.R., Edwards P.A.:Natural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activation. J Biol Chem 2003;278;104-10.
PubMed
38) Pullinger C.R.,Eng C.,Salen G.et al:Human cholesterol 7alpha-hydroxylaseCYP7A1) deficiency has a hypercholesterolemic phenotype. J Clin Invest 2002;110;109-17.
 
39) Sinal C.J., Tohkin M., Miyata M. et al:Targeted disruption of the nucleareceptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 2000;102; 731-44.ile acid receptor. J Biol Chem 2001;276;28857-65. 731-44.
 
40) Miller N.E., Nestel P.J.:Triglyceride-lowering effect of chenodeoxycholiccid in patients with endogenous hypertriglyceridaemia. Lancet 1974;2;92931.
 
41) Angelin B., Einarsson K., Hellstrom K. et al:Effects of cholestyramine andhenodeoxycholic acid on the metabolism of endogenous triglyceride inyperlipoproteinemia. J Lipid Res 1978;19;1017-24.
 
42) Bateson M.C., Maclean D., Evans J.R. et al:Chenodeoxycholic acid therapyor hypertriglyceridaemia in men. Br J Clin Pharmacol 1978;5;249-54.
 
43) Carulli N., Ponz de Leon M., Podda M. et al:Chenodeoxycholic acid andrsodeoxycholic acid effects in endogenous hypertriglyceridemias. Aontrolled double-blind trial. J Clin Pharmacol 1981;21;436-42.
 
44) Watanabe M.,Houten S.M.,Wang L.et al:Bile acids lower triglyceride levelsia a pathway involving FXR,SHP,and SREBP-1c.J Clin Invest 2004;113; 1408-18.
PubMed
45) Repa J.J.,Liang G.,Ou J.et al:Regulation of mouse sterol regulatory elementbinding protein-1c gene(SREBP-1c)by oxysterol receptors,LXRalpha andXRbeta. Genes Dev 2000;14;2819-30.
PubMed
46) Lambert G.,Amar M.J.,Guo G.et al:The farnesoid X-receptor is an essentialegulator of cholesterol homeostasis. J Biol Chem 2003;278;2563-70.
PubMed
47) Kast H.R., Nguyen C.M., Sinal C.J. et al:Farnesoid X-activated receptornduces apolipoprotein C-II transcription:a molecular mechanism linkinglasma triglyceride levels to bile acids. Mol Endocrinol 2001;15;1720-8.
PubMed
48) Claudel T.,Inoue Y.,Barbier O.et al:Farnesoid X receptor agonists suppressepatic apolipoprotein CIII expression. Gastroenterology 2003;125;544-55.
PubMed
49) Hirokane H., Nakahara M., Tachibana S. et al:Bile acid reduces the secretionf very low density lipoprotein by repressing microsomal triglycerideransfer protein gene expression mediated by hepatocyte nuclear factor-4. Jiol Chem 2004;279;45685-92.
 
50) Li J.,Pircher P.C.,Schulman I.G.et al:Regulation of complement C3 expressiony the bile acid receptor FXR. J Biol Chem 2005;280;7427-34.
PubMed
51) Sirvent A.,Claudel T.,Martin G.et al:The farnesoid X receptor induces veryow density lipoprotein receptor gene expression. FEBS Lett 2004;566;1737.
 
52) Pineda Torra I.,Claudel T.,Duval C.et al:Bile Acids Induce the Expressionf the Human Peroxisome Proliferator-Activated Receptor alpha Gene viactivation of the Farnesoid X Receptor. Mol Endocrinol 2003;17;259-72.
 
53) Savkur R.S., Bramlett K.S., Michael L.F. et al:Regulation of pyruvateehydrogenase kinase expression by the farnesoid X receptor. Biochemiophys Res Commun 2005;329;391-6.
PubMed
54) Watanabe M.,Houten S.M.,Mataki C.et al:Bile acids induce energy expenditurey promoting intracellular thyroid hormone activation. Nature 2006.
PubMed
55) Bianco A.C., Salvatore D., Gereben B. et al:Biochemistry, cellular andolecular biology, and physiological roles of the iodothyronineelenodeiodinases. Endocr Rev 2002;23;38-89.
PubMed
56) Baxter J.D.,Webb P.,Grover G.et al:Selective activation of thyroid hormoneignaling pathways by GC-1:a new approach to controlling cholesterol andody weight. Trends Endocrinol Metab 2004;15;154-7.
 
57) Kobayashi M., Ikegami H., Fujisawa T. et al:Prevention and treatment ofbesity, insulin resistance, and diabetes by bile acid-binding resin. Diabetes 2007;56;239-47.
PubMed
58) 梶山梧朗ほか: 新規陰イオン交換樹脂MCI-196のヒト胆汁脂質に与える影響について. 臨床医薬 1996; 12; 1349-59.
Medical*Online
59) Suzuki T., Oba K., Futami S. et al:Blood glucose-lowering activity ofolestimide in patients with type 2 diabetes and hypercholesterolemia:a casecontrol study comparing colestimide with acarbose.J Nippon Med Sch 2006; 73;277-84.
PubMed
60) Yamakawa T., Takano T., Utsunomiya H. et al:Effect of colestimide therapyor glycemic control in type 2 diabetes mellitus with hypercholesterolemia.ndocr J 2007;54;53-8.
 
61) Zieve F.J., Kalin M.F., Schwartz S.L. et al:Results of the glucose-loweringffect of WelChol study(GLOWS):a randomized, double-blind, placebocontrolled pilot study evaluating the effect of colesevelam hydrochloride onlycemic control in subjects with type 2 diabetes. Clin Ther 2007;29;74-83.
PubMed
62) Yamagata K., Daitoku H., Shimamoto Y. et al:Bile acids regulateluconeogenic gene expression via small heterodimer partner-mediatedepression of hepatocyte nuclear factor 4 and Foxo1. J Biol Chem 2004;279; 23158-65.
PubMed
63) Borgius L.J., Steffensen K.R., Gustafsson J.A. et al:Glucocorticoid signalings perturbed by the atypical orphan receptor and corepressor SHP. J Biolhem 2002;277;49761-6.
PubMed
64) Ma K.,Saha P.K.,Chan L.et al:Farnesoid X receptor is essential for normallucose homeostasis. J Clin Invest 2006;116;1102-9.
PubMed
65) Zhang Y.,Lee F.Y.,Barrera G.et al:Activation of the nuclear receptor FXRmproves hyperglycemia and hyperlipidemia in diabetic mice.Proc Natl Acadci U S A 2006;103;1006-11.
PubMed
66) Stayrook K.R.,Bramlett K.S.,Savkur R.S.et al:Regulation of carbohydrateetabolism by the farnesoid X receptor. Endocrinology 2005;146;984-91.
PubMed
67) Kim Y.D., Park K.G., Lee Y.S. et al:Metformin inhibits hepaticluconeogenesis through AMP-activated protein kinase dependent regulationf the orphan nuclear receptor SHP. Diabetes 2007.
PubMed
68) Zhang Y.,Castellani L.W.,Sinal C.J.et al:Peroxisome proliferator-activatedeceptor-gamma coactivator 1alpha(PGC-1alpha)regulates triglycerideetabolism by activation of the nuclear receptor FXR. Genes Dev 2004;18; 157-69.
PubMed
69) Duran-Sandoval D., Mautino G., Martin G. et al:Glucose regulates thexpression of the farnesoid X receptor in liver. Diabetes 2004;53;890-8.
 
70) Wang L., Liu J., Saha P. et al:The orphan nuclear receptor SHP regulatesGC-1alpha expression and energy production in brown adipocytes. Celletab 2005;2;227-38.
 
71) Cariou B., van Harmelen K., Duran-Sandoval D. et al:The farnesoid Xeceptor modulates adiposity and peripheral insulin sensitivity in mice.J Biolhem 2006;281;11039-49.
PubMed
72) Kharitonenkov A., Shiyanova T.L., Koester A. et al:FGF-21 as a noveletabolic regulator. J Clin Invest 2005;115;1627-35.
PubMed
73) Badman M.K., Pissios P., Kennedy A.R. et al:Hepatic Fibroblast Growthactor 21 Is Regulated by PPARalpha and Is a Key Mediator of Hepaticipid Metabolism in Ketotic States. Cell Metab 2007;5;426-437.
PubMed
74) Inagaki T., Dutchak P., Zhao G. et al:Endocrine Regulation of the Fastingesponse by PPARalpha-Mediated Induction of Fibroblast Growth Factor 21. Cell Metab 2007;5;415-25.
PubMed
75) Yu C.,Wang F.,Kan M.et al:Elevated cholesterol metabolism and bile acidynthesis in mice lacking membrane tyrosine kinase receptor FGFR4. J Biolhem 2000;275;15482-9.
 
76) Lundasen T., Galman C., Angelin B. et al:Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J Intern Med 2006;260;530-6.
 
77) Tomlinson E.,Fu L.,John L.et al:Transgenic mice expressing human fibroblastrowth factor-19 display increased metabolic rate and decreaseddiposity. Endocrinology 2002;143;1741-7.
 
78) Fu L., John L.M., Adams S.H. et al:Fibroblast growth factor 19 increasesetabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 2004;145;2594-603.
 
79) Huang X.,Yang C.,Luo Y.et al:FGFR4 prevents hyperlipidemia and insulinesistance but underlies high-fat diet induced fatty liver. Diabetes 2007;56; 2501-10.
 
80) Brown M.S., Goldstein J.L.:A receptor-mediated pathway for cholesterolomeostasis. Science 1986;232;34-47.
PubMed

第III編 肥満病態と食品・医薬品による予防・治療

P.194 掲載の参考文献
1) Zhang Y.,Proenca R.,Maffei M.et al:Positional cloning of the mouse obeseene and its human homologue. Nature 1994;372;425-432.
PubMed
2) Maeda K.,Okubo K., Shimomura I.et al:cDNA cloning and expression of aovel adipose specific collagen-like factor, apM1 (AdiPose Most abundantene transcript 1). Biochem Biophys Res Commun 1996;221;286-289.
PubMed
3) Masuzaki H., Ogawa Y., Sagawa N. et al:Nonadipose tissue production ofeptin:leptin as a novel placenta-derived hormone in humans.Nat Med 1997; 3;1029-1033.
PubMed
4) Bado A., Levasseur S., Attoub S. et al:The stomach is a source of leptin.ature 1998;394;790-793.
 
5) Smith-Kirwin S.M., O'Connor D.M., De Johnston J. et al:Leptin expression in human mammary epithelial cells and breast milk. J Clin Endocrinol Metab 1998;83;1810-1813.
 
6) Aoki N., Kawamura M., Matsuda T.:Lactation-dependent down regulationf leptin production in mouse mammary gland. Biochim Biophys Acta 1999; 1427;298-306.
PubMed
7) Hosoda K.,Masuzaki H.,Ogawa Y.et al:Development of radioimmunoassayor human leptin. Biochem Biophys Res Commun 1996;221;234-239.
PubMed
8) Bjorbaek C., Kahn B. B.:Leptin signaling in the central nervous system andhe periphery. Recent Prog Horm Res 2004;59;305-331.
 
9) Schwartz M. W., Woods S. C., Porte D. Jr. et al:Central nervous systemontrol of food intake. Nature 2000;404;661-671.
PubMed
10) Montague C. T., Farooqi I. S., Whitehead J. P. et al:Congenital leptineficiency is associated with severe early-onset obesity in humans. Nature 1997;387;903-908.
PubMed
11) Strobel A., Issad T., Camoin L. et al:A leptin missense mutation associatedith hypogonadism and morbid obesity. Nat Genet 1998;18;213-215.
PubMed
12) Clement K., Vaisse C., Lahlou N. et al:A mutation in the human leptineceptor gene causes obesity and pituitary dysfunction.Nature 1998;392;398401.
 
13) Ogawa Y.,Masuzaki H.,Hosoda K.et al:Increased glucose metabolism andnsulin sensitivity in transgenic skinny mice overexpressing leptin. Diabetes 1999;48;1822-1829.
PubMed
14) Aizawa-Abe M., Ogawa Y., Masuzaki H. et al:Pathophysiological role ofeptin in obesity-related hypertension. J Clin Invest 2000;105;1243-1252.
PubMed
15) Yura S., Ogawa Y., Sagawa N. et al:Accelerated puberty and late-onsetypothalamic hypogonadism in female transgenic skinny mice overexpressingeptin. J Clin Invest 2000;105;749-755.
PubMed
16) Ebihara K., Ogawa Y., Masuzaki H. et al:Transgenic overexpression ofeptin rescues insulin resistance and diabetes in a mouse model of lipoatrophiciabetes. Diabetes 2001;50;1440-1448.
 
17) Ebihara K., Masuzaki H.,Nakao K.:Long-term leptin-replacement therapyor lipoatrophic diabetes. N Engl J Med 2004;351;615-616.
 
18) Scherer P. E., Williams S., Fogliano M. et al:A novel serum protein similaro C1q, produced exclusively in adipocytes. J Biol Chem 1995;270;2674626749.
PubMed
19) Hu E., Liang P., Spiegelman B. M.:AdipoQ is a novel adipose-specific geneysregulated in obesity. J Biol Chem 1996;271;10697-10703.
 
20) Nakano Y., Tobe T., Choi-Miura N.H. et al:Isolation and characterizationf GBP28, a novel gelatin-binding protein purified from human plasma. Jiochem (Tokyo)1996;120;803-812.
 
21) Shapiro L., Scherer P. E.:The crystal structure of a complement-1q familyrotein suggests an evolutionary link to tumor necrosis factor.Curr Biol 1998; 8;335-338.
PubMed
22) Yokota T.,Oritani K.,Takahashi I.et al:Adiponectin,a new member of theamily of soluble defense collagens, negatively regulates the growth ofyelomonocytic progenitors and the functions of macrophages. Blood 2000; 96;1723-1732.
PubMed
23) Pajvani U. B., Du X., Combs T. P. et al:Structure-function studies of thedipocyte-secreted hormone Acrp30/adiponectin. Implications fpr metabolicegulation and bioactivity. J Biol Chem 2003;278;9073-9085.
PubMed
24) Waki H., Yamauchi T.,Kamon J. et al:Impaired multimerization of humandiponectin mutants associated with diabetes. Molecular structure andultimer formation of adiponectin. J Biol Chem 2003;278;40352-40363.
PubMed
25) Ryo M., Nakamura T., Kihara S. et al:Adiponectin as a biomarker of theetabolic syndrome. Circ J 2004;68;975-981.
PubMed
26) Matsushita K., Yatsuya H., Tamakoshi K. et al:Comparison of circulatingdiponectin and proinflammatory markers regarding their association withetabolic syndrome in Japanese men. Arterioscler Thromb Vasc Biol 2006; 26;871-876.
PubMed
27) Pischon T., Girman C. J.,Hotamisligil G. S. et al:Plasma adiponectin levelsnd risk of myocardial infarction in men. Jama 2004;291;1730-1737.
PubMed
28) Furukawa S., Fujita T., Shimabukuro M. et al:Increased oxidative stress inbesity and its impact on metabolic syndrome. J Clin Invest 2004;114;17521761.
 
29) Pischon T., Girman C. J., Rifai N. et al:Association between dietary factors and plasma adiponectin concentrations in men. Am J Clin Nutr 2005;81;780-786.
PubMed
30) Yamauchi T., Kamon J., Waki H. et al:The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7;941-946.
PubMed
31) Furuhashi M.,Ura N.,Higashiura K.et al:Blockade of the renin-angiotensinystem increases adiponectin concentrations in patients with essential hypertension.ypertension 2003;42;76-81.
 
32) Koh K. K., Quon M. J., Han S. H. et al:Vascular and metabolic effects ofombined therapy with ramipril and simvastatin in patients with type 2iabetes. Hypertension 2005;45;1088-1093.
PubMed
33) Nagasawa A.,Fukui K.,Funahashi T.et al:Effects of soy protein diet on thexpression of adipose genes and plasma adiponectin.Horm Metab Res 2002;34;635-639.
 
34) Flachs P., Mohamed-Ali V., Horakova O. et al:Polyunsaturated fatty acidsf marine origin induce adiponectin in mice fed a high-fat diet.Diabetologia 2006;49;394-397.
 
35) Nagao K., Inoue N., Wang Y. M. et al:Conjugated linoleic acid enhanceslasma adiponectin level and alleviates hyperinsulinemia and hypertension inucker diabetic fatty (fa/fa) rats. Biochem Biophys Res Commun 2003;310;562-566.
PubMed
36) Iwaki M., Matsuda M., Maeda N. et al:Induction of adiponectin, a fatderived antidiabetic and antiatherogenic factor, by nuclear receptors.iabetes 2003;52;1655-1663.
 
37) Hara K., Boutin P., Mori Y. et al:Genetic variation in the gene encodingdiponectin is associated with an increased risk of type 2 diabetes in theapanese population. Diabetes 2002;51;536-540.
PubMed
38) Kondo H., Shimomura I., Matsukawa Y. et al:Association of adiponectinutation with type 2 diabetes:a candidate gene for the insulin resistanceyndrome. Diabetes 2002;51;2325-2328.
PubMed
39) Stumvoll M.,Tschritter O.,Fritsche A.et al:Association of the T-G polymorphismn adiponectin (exon 2)with obesity and insulin sensitivity:interactionith family history of type 2 diabetes. Diabetes 2002;51;37-41.
 
40) Menzaghi C., Ercolino T., Di Paola R. et al:A haplotype at the adiponectinocus is associated with obesity and other features of the insulin resistanceyndrome. Diabetes 2002;51;2306-2312.
PubMed
41) Woo J. G., Dolan L. M., Deka R. et al:Interactions between noncontiguousaplotypes in the adiponectin gene ACDC are associated with plasmadiponectin. Diabetes 2006;55;523-529.
PubMed
42) Yamauchi T., Kamon J., Ito Y. et al:Cloning of adiponectin receptors thatediate antidiabetic metabolic effects. Nature 2003;423;762-769.
PubMed
43) Hug C.,Wang J.,Ahmad N.S.et al:T-cadherin is a receptor for hexamericnd high-molecular-weight forms of Acrp30/adiponectin.Proc Natl Acad SciSA 2004;101;10308-10313.
 
44) Yamauchi T.,Kamon J.,Minokoshi Y. et al:Adiponectin stimulates glucosetilization and fatty-acid oxidation by activating AMP-activated proteininase. Nat Med 2002;8;1288-1295.
 
45) Fruebis J., Tsao T. S., Javorschi S. et al:Proteolytic cleavage product of 30kDa adipocyte complement-related protein increases fatty acid oxidation inuscle and causes weight loss in mice. Proc Natl Acad Sci USA 2001;98; 2005-2010.
PubMed
46) Tsuchida A., Yamauchi T., Ito Y. et al:Insulin/Foxo1 pathway regulatesxpression levels of adiponectin receptors and adiponectin sensitivity. J Biolhem 2004;279;30817-30822.
PubMed
47) Tsuchida A., Yamauchi T., Takekawa S. et al:Peroxisome proliferatoractivated receptor (PPAR)alpha activation increases adiponectin receptorsnd reduces obesity-related inflammation in adipose tissue:comparison ofctivation of PPARalpha, PPARgamma, and their combination. Diabetes 2005;54;3358-3370.
PubMed
48) Alessi M., C.Juhan-Vague I.:PAI-1 and the metabolic syndrome:links, causes, and consequences. Arterioscler Thromb Vasc Biol 2006;26;2200-2207.
PubMed
49) Griffiths S. L., Grainger D. J.:Proposal of a novel diabetogenic mechanismnvolving the serpin PAI-1. Bioessays 2006;28;629-641.
PubMed
50) Mertens I. Van Gaal L. F.:Visceral fat as a determinant of fibrinolysis andemostasis. Semin Vasc Med 2005;5;48-55.
PubMed
51) Skurk T., Hauner H.:Obesity and impaired fibrinolysis:role of adiposeroduction of plasminogen activator inhibitor-1. Int J Obes Relat Metabisord 2004;28;1357-1364.
 
52) Alessi M. C., Bastelica D., Mavri A. et al:Plasma PAI-1 levels are moretrongly related to liver steatosis than to adipose tissue accumulation.Arteriosclerhromb Vasc Biol 2003;23;1262-1268.
PubMed
53) Ishii M., Yoshioka Y., Ishida W. et al:Liver fat content measured by magneticesonance spectroscopy at 3.0 tesla independently correlates with plasminogenctivator inhibitor-1 and body mass index in type 2 diabetic subjects.ohoku J Exp Med 2005;206;23-30.
 
54) Fukuhara A.,Matsuda M.,Nishizawa M.et al:Visfatin:a protein secreted byisceral fat that mimics the effects of insulin. Science 2005;307;426-430.
PubMed
55) Samal B.,Sun Y.,Stearns G.et al:Cloning and characterization of the cDNAncoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 1994;14;1431-1437.
PubMed
56) Tanaka M.,Nozaki M.,Fukuhara A.et al:Visfatin is released from 3T3-L1dipocytes via a non-classical pathway.Biochem Biophys Res Commun 2007;359;194-201.
 
57) Revollo J.R.,Grimm A.A.,Imai S.:The NAD biosynthesis pathway mediatedy nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalianells. J Biol Chem 2004;279;50754-50763.
 
58) Hammarstedt A., Pihlajamaki J., Rotter Sopasakis V. et al:Visfatin is andipokine, but it is not regulated by thiazolidinediones. J Clin Endocrinoletab 2006;91;1181-1184.
PubMed
59) Curat C. A., Wegner V., Sengenes C. et al:Macrophages in human visceraldipose tissue:increased accumulation in obesity and a source of resistin andisfatin. Diabetologia 2006;49;744-747.
 
60) Berndt J.,Kloting N.,Kralisch S.et al:Plasma visfatin concentrations and fatepot-specific mRNA expression in humans. Diabetes 2005;54;2911-2916.
PubMed
61) Haider D.G.,Holzer G.,Schaller G.et al:The adipokine visfatin is markedlylevated in obese children. J Pediatr Gastroenterol Nutr 2006;43;548-549.
 
62) Haider D. G., Pleiner J., Francesconi M. et al:Exercise training lowerslasma visfatin concentrations in patients with type 1 diabetes.J Clin Endocrinoletab 2006;91;4702-4704.
 
63) Chen M.P.,Chung F.M.,Chang D.M.et al:Elevated plasma level of visfatin/re-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. Clin Endocrinol Metab 2006;91;295-299.
 
64) Segawa K., Fukuhara A., Hosogai N. et al:Visfatin in adipocytes ispregulated by hypoxia through HIF1alpha-dependent mechanism. Biochemiophys Res Commun 2006;349;875-882.
PubMed
65) Bae S. K., Kim S. R., Kim J. G. et al:Hypoxic induction of human visfatinene is directly mediated by hypoxia-inducible factor-1. FEBS Lett 2006;580;4105-4113.
PubMed
66) Haider D.G.,Schaller G.,Kapiotis S.et al:The release of the adipocytokineisfatin is regulated by glucose and insulin.Diabetologia 2006;49;1909-1914.
PubMed
67) Kralisch S., Klein J., Lossner U. et al:Hormonal regulation of the noveldipocytokine visfatin in 3T3-L1 adipocytes. J Endocrinol 2005;185;R1-8.
PubMed
68) Carswell E. A., Old L. J., Kassel R. L. et al:An endotoxin-induced serumactor that causes necrosis of tumors.Proc Natl Acad Sci USA 1975;72;36663670.
 
69) Hotamisligil G. S., Shargill N. S.Spiegelman B. M.:Adipose expression ofumor necrosis factor-alpha:direct role in obesity-linked insulin resistance.cience 1993;259;87-91.
 
70) Uysal K. T., Wiesbrock S. M., Marino M. W. et al:Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997;389;610-614.
PubMed
71) Kern P.A.,Saghizadeh M.,Ong J.M.et al:The expression of tumor necrosisactor in human adipose tissue. Regulation by obesity, weight loss, andelationship to lipoprotein lipase. J Clin Invest 1995;95;2111-2119.
PubMed
72) Qi C., Pekala P. H.:Tumor necrosis factor-alpha-induced insulin resistancen adipocytes. Proc Soc Exp Biol Med 2000;223;128-135.
 
73) Ueki K.,Kondo T.,Kahn C. R.:Suppressor of cytokine signaling 1 (SOCS-1)nd SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylationf insulin receptor substrate proteins by discrete mechanisms. Molell Biol 2004;24;5434-5446.
 
74) Holcomb I. N., Kabakoff R. C., Chan B. et al:FIZZ1, a novel cysteine-richecreted protein associated with pulmonary inflammation,defines a new geneamily. Embo J 2000;19;4046-4055.
 
75) Steppan C.M.,Bailey S.T.,Bhat S.et al:The hormone resistin links obesityo diabetes. Nature 2001;409;307-312.
 
76) Banerjee R. R., Lazar M.A.:Dimerization of resistin and resistin-like moleculess determined by a single cysteine. J Biol Chem 2001;276;25970-25973.
 
77) Haugen F., Jorgensen A., Drevon C.A. et al:Inhibition by insulin of resistinene expression in 3T3-L1 adipocytes. FEBS Lett 2001;507;105-108.
PubMed
78) Shojima N., Sakoda H., Ogihara T. et al:Humoral regulation of resistinxpression in 3T3-L1 and mouse adipose cells. Diabetes 2002;51;1737-1744.
PubMed
79) Nogueiras R., Gualillo O., Caminos J. E. et al:Regulation of resistin byonadal,thyroid hormone,and nutritional status.Obes Res 2003;11;408-414.
PubMed
80) Ghosh S., Singh A. K., Aruna B. et al:The genomic organization of mouseesistin reveals major differences from the human resistin:functional implications.ene 2003;305;27-34.
 
81) Moon B., Kwan J. J., Duddy N. et al:Resistin inhibits glucose uptake in L6 cells independently of changes in insulin signaling and GLUT4 translocation. Am J Physiol Endocrinol Metab 2003;285;E106-115.
PubMed
82) Banerjee R.R.,Rangwala S.M.,Shapiro J.S.et al:Regulation of fasted bloodlucose by resistin. Science 2004;303;1195-1198.
PubMed
83) Rangwala S.M.,Rich A.S.,Rhoades B.et al:Abnormal glucose homeostasisue to chronic hyperresistinemia. Diabetes 2004;53;1937-1941.
PubMed
84) McTernan C.L.,McTernan P.G.,Harte A.L.et al:Resistin,central obesity,nd type 2 diabetes. Lancet 2002;359;46-47.
 
85) Otto C., Otto B., Goke B. et al:Increase in adiponectin levels during pioglitazoneherapy in relation to glucose control, insulin resistance as well ashrelin and resistin levels. J Endocrinol Invest 2006;29;231-236.
 
86) Sartipy P., Loskutoff D. J.:Monocyte chemoattractant protein 1 in obesitynd insulin resistance. Proc Natl Acad Sci USA 2003;100;7265-7270.
PubMed
87) Kanda H., Tateya S., Tamori Y. et al:MCP-1 contributes to macrophagenfiltration into adipose tissue, insulin resistance, and hepatic steatosis inbesity. J Clin Invest 2006;116;1494-1505.
 
88) Berg A. H., Scherer P. E.:Adipose tissue, inflammation, and cardiovascularisease. Circ Res 2005;96;939-949.
PubMed
89) Wellen K. E., Hotamisligil G. S.:Inflammation, stress, and diabetes. J Clinnvest 2005;115;1111-1119.
PubMed
90) Xu H., Barnes G. T., Yang Q. et al:Chronic inflammation in fat plays arucial role in the development of obesity-related insulin resistance. J Clinnvest 2003;112;1821-1830.
PubMed
91) Tsuchiya K.,Yoshimoto T.,Hirono Y.et al:Angiotensin II induces monocytehemoattractant protein-1 expression via a nuclear factor-kappaB-dependentathway in rat preadipocytes.Am J Physiol Endocrinol Metab 2006;291;771-778.
 
92) Takahashi K.,Mizuarai S.,Araki H.et al:Adiposity elevates plasma MCP-1evels leading to the increased CD11b-positive monocytes in mice. J Biolhem 2003;278;46654-46660.
 
93) Kamei N., Tobe K., Suzuki R. et al:Overexpression of monocytehemoattractant protein-1 in adipose tissues causes macrophage recruitmentnd insulin resistance. J Biol Chem 2006;281;26602-26614.
PubMed
94) Weisberg S.P.,Hunter D.,Huber R.et al:CCR2 modulates inflammatory andetabolic effects of high-fat feeding. J Clin Invest 2006;116;115-124.
PubMed
95) Aoki N.,Jin-no S.,Nakagawa Y.et al:Identification and characterization oficrovesicles secreted by 3T3-L1 adipocytes:redox-and hormone-dependentnduction of milk fat globule-epidermal growth factor 8-associatedicrovesicles. Endocrinology 2007;148;3850-3862.
PubMed

第10章 脂肪組織リモデリングの分子機構と医学応用

P.213 掲載の参考文献
1) Xu H., Barnes G. T., Yang Q. et al:Chronic inflammation in fat plays arucial role in the development of obesity-related insulin resistance. J Clinnvest 2003;112;1821-1830.
PubMed
2) Hotamisligil G.S.:Inflammation and metabolic disorders.Nature 2006;444;860-867.
PubMed
3) Weisberg S. P., McCann D., Desai M. et al:Obesity is associated withacrophage accumulation in adipose tissue. J Clin Invest 2003;112;17961808.
 
4) Wellen K. E., Hotamisligil G. S.:Inflammation, stress, and diabetes. J Clinnvest 2005;115;1111-1119.
PubMed
5) Skurk T.,Alberti-Huber C.,Herder C.et al:Relationship between adipocyteize and adipokine expression and secretion. J Clin Endocrinol Metab 2007;92;1023-1033.
PubMed
6) Kanda H., Tateya S., Tamori Y. et al:MCP-1 contributes to macrophagenfiltration into adipose tissue, insulin resistance, and hepatic steatosis inbesity. J Clin Invest 2006;116;1494-1505.
 
7) Weisberg S. P., McCann D., Desai M. et al:CCR2 modulates inflammatorynd metabolic effects of high-fat feeding. J Clin Invest 2006;116;115-124.
 
8) Kamei N., Tobe K., Suzuki R. et al:Overexpression of monocytehemoattractant protein-1 in adipose tissues causes macrophage recruitmentnd insulin resistance. J Biol Chem 2006;281;26602-26614.
PubMed
9) Chow F.Y.,Nikolic-Paterson D.J.,Ma F.Y.et al:Monocyte chemoattractantrotein-1-induced tissue inflammation is critical for the development of renalnjury but not type 2 diabetes in obese db/db mice.Diabetologia 2007;50;471480.
PubMed
10) Inouye K. E., Shi H., Howard J.K. et al:Absence of CC chemokine ligand 2oes not limit obesity-associated infiltration of macrophages into adiposeissue. Diabetes 2007;56;2242-2250.
 
11) Nomiyama T.,Perez-Tilve D.,Ogawa D.et al:Osteopontin mediates obesityinduced adipose tissue macrophage infiltration and insulin resistance in mice. Clin Invest 2007;117;2877-2888.
PubMed
12) Hosogai N.,Fukuhara A.,Oshima K.et al:Adipose tissue hypoxia in obesitynd its impact on adipocytokine dysregulation. Diabetes 2007;56;901-911.
PubMed
13) Furukawa S., Fujita T., Shimabukuro M. et al:Increased oxidative stress inbesity and its impact on metabolic syndrome. J Clin Invest 2004;114;17521761.
 
14) Ozcan U.,Cao Q.,Yilmaz E.et al:Endoplasmic reticulum stress links obesity,nsulin action, and type 2 diabetes. Science 2004;306;457-461.
 
15) Ozcan U., Yilmaz E., Ozcan L. et al:Chemical chaperones reduce ER stressnd restore glucose homeostasis in a mouse model of type 2 diabetes.Science 2006;313;1137-1140.
 
16) Ito A.,Suganami T.,Miyamoto Y.et al:Role of MAPK phosphatase-1 in thenduction of monocyte chemoattractant protein-1 during the course ofdipocyte hypertrophy. J Biol Chem 2007;282;25445-25452.
PubMed
17) Wu J. J., Roth R. J., Anderson E. J. et al:Mice lacking MAP kinase phosphatase-1 have enhanced MAP kinase activity and resistance to diet-inducedbesity. Cell Metab 2006;4;61-73.
PubMed
18) Cinti S.,Mitchell G.,Barbatelli G.et al:Adipocyte death defines macrophageocalization and function in adipose tissue of obese mice and humans.J Lipides 2005;46;2347-2355.
PubMed
19) Suganami T., Nishida J., Ogawa Y.:A paracrine loop between adipocytes and macrophages aggravates inflammatory changes:role of free fatty acids and tumor necrosis factor α. Arterioscler Thromb Vasc Biol 2005;25;2062-2068.
 
20) Suganami T., Tanimoto-Koyama K., Nishida J. et al:Role of the Toll-like receptor 4/NF-κB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages. Arterioscler Thromb Vasc Biol 2007;27;84-91.
 
21) Suganami T.,Mieda T.,Itoh M.et al:Attenuation of obesity-induced adiposeissue inflammation in C3H/HeJ mice carrying a Toll-like receptor 4 mutation.iochem Biophys Res Commun 2007;354;45-49.
 
22) Shi H., Kokoeva M. V., Inouye K. et al:TLR4 links innate immunity andatty acid-induced insulin resistance. J Clin Invest 2006;116;3015-3025.
PubMed
23) Lee J. Y., Sohn K. H., Rhee S. H. et al:Saturated fatty acids, but notnsaturated fatty acids,induce the expression of cyclooxygenase-2 mediatedhrough Toll-like receptor 4. J Biol Chem 2001;276;16683-16689.
PubMed
24) Lee J. Y., Plakidas A., Lee W.H. et al:Differential modulation of Toll-likeeceptors by fatty acids:preferential inhibition by n-3 polyunsaturated fattycids. J Lipid Res 2003;44;479-486.
 
25) Kromhout D., Bosschieter E. B., de Lezenne Coulander C.:The inverse relationetween fish consumption and 20-year mortality from coronary heartisease. N Engl J Med 1985;312;1205-1209.
PubMed
26) Siscovik D. S., Raghunathan T. E., King I. et al:Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. JAMA 1995;274;1363-1367.
 
27) Burr M.L.,Fehily A.M.,Gilbert J.F.et al:Effects of changes in fat,fish,andibre intakes on death and myocardial reinfarction:diet and reinfarction trialDART). Lancet 1989;2;757-761.
PubMed
28) Yokoyama M., Origasa H., Matsuzaki M. et al:Effects of eicosapentaenoiccid on major coronary events in hypercholesterolaemic patients (JELIS):aandomised open-label, blinded endpoint analysis. Lancet 2007;369;10901098.
 
29) Satoh N., Shimatsu A., Kotani K. et al:Purified eicosapentaenoic acideduces small dense LDL, remnant lipoprotein particles, and C-reactiverotein in metabolic syndrome. Diabetes Care 2007;30;144-146.
 
30) Itoh M., Suganami T., Satoh N. et al:Increased adiponectin secretion byighly purified eicosapentaenoic acid in rodent models of obesity and humanbese subjects. Arterioscler Thromb Vasc Biol 2007;27;1918-1925.
PubMed
31) Gordon S.:Alternative activation of macrophages.Nat Rev Immunol 2003;3;23-35.
PubMed
32) Mantovani A., Sica A., Sozzani S. et al:The chemokine system in diverseorms of macrophage activation and polarization.Trends Immunol 2004;25;677-686.
PubMed
33) Odegaard J. I., Ricardo-Gonzalez R. R., Goforth M. H. et al:Macrophagespecific PPARg controls alternative activation and improves insulin resistance.ature 2007;447;1116-1120.
 
34) Lumeng C. N., Bodzin J. L., and Saltiel A. R.:Obesity induces a phenotypicwitch in adipose tissue macrophage polarization.J Clin Invest 2007;117;175184.
 
35) Bouhlel M. A., Derudas B., Rigamonti E. et al:PPARg activation primesuman monocytes into alternative M2 macrophages with anti-inflammatoryroperties. Cell Metab 2007;6;137-143.
 

第11章 肥満・メタボリックシンドロームと食品機能

P.235 掲載の参考文献
1) メタボリックシンドローム診断基準検討委員会: メタボリックシンドロームの疾患概念の確立と診断基準の設定. 2005.
 
2) Lagouge M., Argmann C., Gerhart-Hines Z. et al:Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α. Cell 2006;127;1-14.
 
3) Tsuboyama-Kasaoka N., Shozawa C., Sano K. et al:Taurine (2-aminoethanesulfoniccid) deficiency creates a vicious circle promoting obesity.ndocrinology 2006;147;3276-3284.
PubMed
4) Kim M.S.,Park J.Y.,Namkoong C.et al:Anti-obesity effects of alpha-lipoiccid mediated by suppression of hypothalamic AMP-activated protein kinase.at Med 2004;10;727-733.
PubMed
5) Goto K., Kasaoka S., Takizawa M. et al:Bitter taste and blood glucose areot involved in the suppressive effect of dietary histidine on food intake.eurosci Lett 2007;420;106-109.
PubMed
6) Houstis N., Rosen E.D., Lander E.S.:Reactive oxygen species have a causalole in multiple forms of insulin resistance. Nature 2006;440;944-948.
PubMed
7) Ford E.S., Mokdad A.H., Giles W.H. et al:The metabolic syndrome andntioxidant concentrations:findings from the Third National Health andutrition Examination Survey. Diabetes 2003;52;2346-2352.
PubMed
8) Weisberg S.P.,McCann D.,Desai M.et al:Obesity is associated with macrophageccumulation in adipose tissue. J Clin Invest 2003;112;1796-1808.
PubMed
9) Xu H.,Barnes G.T.,Yang Q.et al:Chronic inflammation in fat plays a crucialole in the development of obesity-related insulin resistance. J Clin Invest 2003;112;1821-1830.
 
10) Chawla A.,Repa J.J.,Evans R.M.et al:Nuclear Receptors and Lipid Physiology:pening the X-Files. Science 2001;294;1866-1870.
 
11) Lazar M.A.:East meets West:an herbal tea finds a receptor. J Clin Invest 2004;113;23-25.
 
12) Takahashi N., Kawada T., Goto T. et al:Dual action of isoprenols from herbal medicines on both PPARγ and PPARα in 3T3-L1 adipocytes and HepG2 hepatocytes. FEBS Lett 2002;514;315-322.
 
13) Takahashi N., Kawada T., Goto T. et al:Abietic acid activates peroxisome proliferator-activated receptor-gamma (PPARγ)in RAW264.7 macrophages and 3T3-L1 adipocytes to regulate gene expression involved in inflammation and lipid metabolism. FEBS Lett 2003;550;190-194.
 
14) Park J.Y., Kawada T., Han I.S. et al:Capsaicin inhibits the production of tumor necrosis factor alpha by LPS-stimulated murine macrophages, RAW 264.7:a PPARγ ligand-like action as a novel mechanism. FEBS Lett 2004;572;266-270.
 
15) Goto T., Takahashi N., Kato S. et al:Phytol directly activates peroxisome proliferator-activated receptor alpha (PPARα)and regulates gene expression involved in lipid metabolism in PPARα-expressing HepG2 hepatocytes. Biochem Biophys Res Commun 2005;337;440-445.
 
16) Kuroyanagi K., Kang M.S., Goto T. et al:Citrus auraptene acts as an agonist for PPARs and enhances adiponectin production and MCP-1 reduction in 3T3-L1 adipocytes. Biochem Biophys Res Commun;2007;in press.
 
17) Yajima H., Ikeshima E., Shiraki M. et al:Isohumulones, bitter acids derived from hops, activate both peroxisome proliferator-activated receptor α and γ and reduce insulin resistance. J Biol Chem 2004;279;33456-33462.
 
18) Claudel T.,Staels B.,Kuipers F.:The Farnesoid X receptor:a molecular linketween bile acid and lipid and glucose metabolism. Arterioscler Thrombasc Biol 2005;10;2020-2030.
PubMed
19) Zelcer N., Tontonoz P.:Liver X receptors as integrators of metabolic andnflammatory signaling. J Clin Invest 2006;116;607-614.
PubMed
20) Yu R., Kim C.S., Kwon B.S. et al:Mesenteric adipose tissue-derivedonocyte chemoattractant protein-1 plays a crucial role in adipose tissueacrophage migration and activation in obese mice. Obesity 2006;14;13531362.
 
21) Kang J.H., Kim C.S., Han I.S. et al:Capsaicin, a spicy component of hoteppers,modulates adipokine gene expression and protein release from obesemouse adipose tissues and isolated adipocytes,and suppresses the inflammatoryesponses of adipose tissue macrophages. FEBS Lett 2007;581;43894396.
PubMed
22) Woo H.M.,Kang J.H.,Kawada T.et al:Active spice-derived components cannhibit inflammatory responses of adipose tissue in obesity by suppressingnflammatory actions of macrophages and release of monocytehemoattractant protein-1 from adipocytes. Life Sci 2007;80;926-931.
PubMed
23) Hirai S.,Kim Y.I., Goto T. et al:Inhibitory effect of naringenin chalcone onnflammatory changes in the interaction between adipocytes and macrophages.ife Sci 2007;81;1272-1279.
 
24) Tsuda T., Horio F., Uchida K et al:Dietary cyanidin 3-O-beta-D-glucoside-rich purple corn color prevents obesity and ameliorates hyperglycemia in mice. J Nutr 2003;133;125-130.
 
25) Sasaki R.,Nishimura N.,Hoshino H.et al:Cyanidin 3-glucoside amelioratesyperglycemia and insulin sensitivity due to downregulation of retinol bindingrotein 4 expression in diabetic mice. Biochem Pharmacol 2007;74;16191627.
 
26) Yang Q., Graham T.E., Mody N. et al:Serum retinol binding protein 4 contributeso insulin resistance in obesity and type 2 diabetes.Nature 2005;436;356-362.
PubMed
27) Tsuda T.,Ueno Y.,Yoshikawa T.et al:Microarray profiling of gene expressionn human adipocytes in response to anthocyanins. Biochem Pharmacol 2006;71;1184-1197.
 
28) 上野有紀: クルクミノイド類. 抗肥満食品・素材の開発と応用展開; 抗肥満のメカニズム-メタボリックシンドロームにおけるバイオマーカーの確立と応用-(大澤俊彦 監修) シーエムシー出版, 2007, p157-164.
 
29) 津田孝範: 食品因子による脂肪細胞機能の制御の可能性. ジャパンフードサイエンス 2005; 44; 29-36.
 
30) Itoh M., Suganami T., Satoh N. et al:Increased adiponectin secretion byighly purified eicosapentaenoic acid in rodent models of obesity and humanbese subjects. Arterioscler Thromb Vasc Biol 2007;27;1918-1925.
PubMed
31) Perez-Matute P.,Martinez J.A.,Marti A.et al:Linoleic Acid decreases leptinnd adiponectin secretion from primary rat adipocytes in the presence ofnsulin. Lipids 2007;42;913-920.
PubMed
32) Park P.H., McMullen M.R., Huang H. et al:Short-term treatment of RAW264.7 macrophages with adiponectin increases tumor necrosis factor-α(TNF-α) expression via ERK1/2 activation and Egr-1 expression:role of TNF-α in adiponectin-stimulated interleukin-10 production. J Biol Chem 2007;282;21695-21703.
 
33) Kumada M., Kihara S., Ouchi N. et al:Adiponectin specifically increasedissue inhibitor of metalloproteinase-1 through interleukin-10 expression inuman macrophages. Circulation 2004;109;2046-2049.
 
34) Unoki H.,Bujo H.,Shibasaki M.et al:Increased matrix metalloproteinase-3RNA expression in visceral fat in mice implanted with culturedreadipocytes. Biochem Biophys Res Commun 2006;350;392-398.
 

第12章 脂肪細胞制御による肥満・糖尿病治療の可能性とその展望

P.250 掲載の参考文献
1) http://www.cdc.gov/diabetes/pubs/estimates05.html
 
2) http://www.kenkounippon21.gr.jp/index.html
 
3) Hausman D.B., DiGirolamo M., Bartness T.J. et al:The biology of whitedipocyte proliferation. Obes Rev 2;239;2001.
PubMed
4) Rosen E.D.,MacDougald O.A.:Adipocyte differentiation from the inside out.at Rev Mol Cell Biol 7;885-896;2006.
 
5) Matsuzawa Y.:Therapy Insight:adipocytokines in metabolic syndrome andelated cardiovascular disease. Nat Clin Pract Cardiovasc Med 3;35-42;2006.
 
6) 杉浦 甫: 肥満についての, 新しい細胞生物学的分類の提唱. 肥満研究 8; 17-22; 2002.
 
7) Sakai T.,Sakaue H.,Nakamura T.et al:Skp2 controls adipocyte proliferationuring the development of obesity. J Biol Chem 282;2038-2046;2007.
 
8) Bjorntorp P.,Karlsson M.,Pettersson P.:Expansion of adipose tissue strongapacity at different ages in rats. Metabolism 31;366-373;1982.
 
9) Dani C.:Embryonic stem cell-derived adipogenesis. Cells Tissues Organs 165;173-180;1999.
 
10) Bost F., Aouadi M., Caron L. et al:The Extracellular Signal-Regulatedinase Isoform ERK1 Is Specifically Required for In Vitro and In Vivodipogenesis. Diabetes 54;402-411;2005.
 
11) Bost F., Caron L., Marchetti I. et al:Retinoic acid activation of the ERKathway is required for embryonic stem cell commitment into the adipocyteineage. Biochem J 361;621-627;2002.
 
12) Loftus T.M., Kuhajda F.P., Lane M.D.:Insulin depletion leads to adiposespecific cell death in obese but not lean mice. Proc Natl Acad Sci USA 95;14168-14172;1998.
PubMed
13) Della-Fera M.A.,Choi Y.H.,Hartzell D.L.et al:Sensitivity of ob/ob mice toeptin-induced adipose tissue apoptosis. Obes Res 13;1540-1547;2005.
 
14) Cinti S., Mitchell G., Murano I. et al.:Adipocyte death defines macrophageocalization and function in adipose tissue of obese mice and humans.J Lipides 46;2347-2355;2005.
 
15) Tang Q.Q., Otto T.C., Lane M.D.:Mitotic clonal expansion:a synchronousrocess required for adipogenesis.Proc Natl Acad Sci USA 100;44-49;2003.
 
16) Rosen E.D., Spiegelman B.M.:Molecular regulation of adipogenesis. Annuev Cell Dev Biol 16;145;2000.
PubMed
17) Kubota N.,Terauchi Y.,Miki H.et al:PPAR gamma mediates high-fat dietinduced adipocyte hypertrophy and insulin resistance.Mol Cell 4;597;1999.
PubMed
18) Fajas L., Landsberg RL., Huss-Garcia Y. et al:E2F regulates adipocyteifferentiation. Dev Cell 3;39-49;2002.
 
19) Abella A., Dubus P., Malumbres M. et al:Cdk4 promotes adipogenesishrough PPARgamma activation. Cell Metab 2;239-249;2005.
 
20) Sarruf D.A., Iankova I., Abella A. et al:Cyclin D3 promotes adipogenesishrough activation of peroxisome proliferators-activated receptor gamma.ol Cell Biol 25;9985-9995;2005.
 
21) Li X., Kim J.W., Gronborg M. et al:Role of cdk2 in the sequential phosphorylation/activation of C/EBPβ during adipocyte differentiation. Proc Natl Acad Sci USA 104;11597-11602;2007.
 
22) Naaz A., Holsberger D.R., Iwamoto G.A. et al:Loss of cyclin-dependentinase inhibitors produces adipocyte hyperplasia and obesity. FASEB J 18;1925-1927;2004.
 
23) Kanda H., Tateya S., Tamori Y. et al:MCP-1 contributes to macrophagenfiltration into adipose tissue, insulin resistance, and hepatic steatosis inbesity. J Clin Invest 116;1494-1505;2006.
 
24) Kamei N., Tobe K., Suzuki R. et al:Overexpression of monocytehemoattractant protein-1 in adipose tissues causes macrophage recruitmentnd insulin resistance. J Biol Chem 281;26602-26614;2006.
 

終章 肥満研究の今後の展望とメタボリックシンドローム対策

P.257 掲載の参考文献
1) 厚生労働省健康局: 平成17年国民健康・栄養調査結果の概要. http://www.mhlw.go.jp/houdou/2007/05/h0516-3.html
 
2) 福原淳範, 下村伊一郎: ビスファチン. Adiposcience 2006; 3; 314-318.
Medical*Online
3) Bell L.N., Cai L., Johnstone B.H.et al:A central role for hepatocyte growthactor in adipose tissue angiogenesis. Am J Physiol Endocrinol Metab 2008;294;E336-44.
PubMed
4) 伊達紫, 中里雅光, 寒川賢治: 消化管ホルモンの神経系を介する摂食調節機構. 肥満研究 2007;13;230-237.
Medical*Online
5) Sui X., LaMonte M.J., Laditka J.N. et al:Cardiorespiratory fitness anddiposity as mortality predictors in older adults.JAMA 2007;298;2507-2516
 

書評

最近チェックした商品履歴

Loading...